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CD137 is a co-stimulatory receptor found on activated T lymphocytes and certain 
cancer cells.   In particular, CD137 was detected on B cells in 14 out of 14 cases 
of chronic lymphocytic leukaemia analysed, but not in healthy B cell samples.  
Thus, this study aims to characterize the potential role of CD137 as a cancer 
neoantigen.  Using cell lines which overexpress CD137, it was found that CD137 
does not protect cancer cells against cell death mediated by lymphokine activated 
killer cells and chemotherapeutic drugs.  Also, CD137-expressing cells do not 
enhance monocyte adhesion, a process which may increase the number of tumour 
associated macrophages.  These in vitro data suggest that CD137 expression does 
not confer a survival advantage upon cancer cells.  Finally, to understand how 
soluble CD137 might disrupt CD137-mediated signaling, this study also aims to 
determine if soluble CD137 associates with membrane-bound CD137.  Our 
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CHAPTER 1  INTRODUCTION  
 
1.1  STRUCTURE AND EXPRESSION OF HUMAN CD137 
 
CD137 (also known as 4-1BB), a type-I transmembrane protein and a member of 
the tumour necrosis factor receptor (TNFR) superfamily, was first identified in the 
mouse in 1989 via the screening of concanavalin A-activated T cells (Kwon & 
Weissman 1989).  Subsequently, its human homologue was isolated from 
activated human T lymphocytes in 1993 (Schwarz et al. 1993). 
 
CD137 comprises 255 amino acids (aa) and has a calculated molecular mass of 27 
kDa.  The first 17 aa were predicted to form a signal peptide.  The next 169 aa 
form the extracellular domain, which is followed by a 27 aa transmembrane 
domain.  Lastly, the remaining 42 aa form the cytoplasmic domain, which is 
necessary for signal transduction into the cell.  Within the extracellular region lie 
four cysteine-rich domains (CRDs) which are characteristic of TNFR superfamily 
members.  The chromosomal location of the CD137 gene has been mapped to 
chromosome band 1p36, where the genes for four other members of the TNFRSF 
- TNFR-2, CD30, OX40 and TRAMP/Apo3, are also found (Schwarz et al. 1997). 
 
CD137 is present on the surfaces of primary T lymphocytes, where its expression 
is strictly activation dependent (Schwarz et al. 1995).  Other immune cells that 
express CD137 include monocytes (Kienzle & von 2000), and follicular dendritic 
cells (DCs) in germinal centres (Pauly et al. 2002).  Besides immune cells, 





inflammatory factors (von et al. 1997).  The walls of blood vessels at sites of 
inflammation (Drenkard et al. 2007) and in malignant tumours (Broll et al. 2001) 
also can express CD137.  In addition, CD137 expression has been reported in 
certain cancers such as in Reed- Sternberg cells in Hodgkin’s lymphoma (Gruss et 
al. 1996a; Gruss et al. 1996b), chronic lymphocytic leukaemia (CLL) (personal 
communication, Schwarz H), osteosarcoma (Lisignoli et al. 1998), 
rhabdomyosarcoma (personal communication, Schwarz H) and pancreatic cancer 
(Ringel et al. 2001). 
 
1.2  STRUCTURE AND EXPRESSION OF HUMAN CD137 LIGAND 
 
Human CD137 Ligand (CD137L or 4-1BBL) is a type-II transmembrane protein 
consisting of 254 aa (Alderson et al. 1994).  Like other members of the tumour 
necrosis factor (TNF) superfamily, it is present in a trimeric form on cell surfaces 
(Rabu et al. 2005). The gene for human CD137L is located on chromosome 
19p13.3 (Alderson et al. 1994). 
 
CD137L is expressed by antigen presenting cells (APCs).  Primary B cells express 
CD137L upon activation, whereas some B cell lines express CD137L 
constitutively (Zhou et al. 1995; Palma et al. 2004).  Constitutive expression can 
be detected on monocytes, macrophages and DCs, albeit DCs express more 
CD137L after pro-inflammatory stimulation.  CD137L expression is inducible in 
T cells by anti-CD3 antibodies (Abs) (Goodwin et al. 1993). A number of human 
carcinoma cell lines derived from the colon, lung, breast, ovary and prostate have 





1.3 ROLE OF CD137 AS A CO-STIMULATORY SIGNALING 
MOLECULE 
 
The crosslinking of CD137 on activated T lymphocytes leads to enhanced 
proliferation (Schwarz et al. 1996), thus establishing its role as a co-stimulatory 
signaling molecule.  CD137 is believed to be upregulated on T cells as a result of 
initial activating signals through the T cell receptor and CD28.  Subsequently, 
CD137 interacts with its ligand which is expressed on APCs, hence providing 
additional co-stimulatory signals to the T lymphocytes.  In CD8+ T cells, 
CD137:CD137L signaling enhances both survival and clonal proliferation, 
whereas only the former is observed in CD4+ T cells (Cheuk et al. 2004). 
 
CD137 is linked via tumour necrosis factor receptor-associated factor (TRAF) 2 to 
downstream signaling pathways (Jang et al. 1998), with the signaling activity of 
TRAF 2 being modulated by TRAF 1.  Trimerisation of TRAF 2 activates 
mitogen activated protein kinases (MAPKs), which in turn activate the c-jun-N-
terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 MAPK 
pathways (Dempsey et al. 2003).  While it is evident that CD137 signaling results 
in nuclear factor-κB (NF-κB) activation (Jang et al. 1998), the exact proteins 
linking CD137/TRAF 2 to the inhibitor of κ B kinase (IKK) complex are 
unknown.  However, NF-κB inducing kinase (NIK) may play a potential role in 
this pathway.  The activation of NF-κB leads to increased expression of the anti-
apoptotic proteins Bcl-XL and Bfl-1, hence preventing activation induced cell 
death (AICD) (Lee et al. 2002).   Together with a signal from the T cell receptor 







Figure 1.  Pathways involved in CD137 (4-1BB) signaling (Watts 2005). 
Reprinted, with permission, from the Annual Review of Immunology, 
Volume 23 © 2005 by Annual Reviews   www.annualreviews.org.   
 
1.4  APPLICATIONS OF CD137 IN IMMUNOTHERAPY 
 
Cell-mediated responses are important for the elimination of cancer cells by the 
immune system.  Since CD137 is a potent co-stimulatory molecule in T cells, it 
has been identified as a potential candidate for anti-tumour immunotherapy.  
Several strategies that aim to engage CD137 on T cells and thus enhance T cell 
activity have been reported.   
 
One of the earliest approaches involved the direct injection of anti-CD137 
monoclonal antibodies (mAbs) into tumour-bearing mice.  In the murine sarcoma 
and mastocytoma models used, the eradication of established tumours was 
observed (Melero et al. 1997).  Subsequently, anti-CD137 mAbs have been 





apoptosis-inducing ligand (TRAIL) (Uno et al. 2006), and with engineered drug-
resistant haematopoietic cells (McMillin et al. 2006).   
 
Various groups have also developed whole cell vaccines to cross-link CD137 on T 
cells.  For instance, mice injected with CD137L-transfected A20 cells (a murine B 
cell lymphoma) did not develop tumours and were resistant to subsequent 
challenge with the parental cell line (Guinn et al. 1999; Guinn et al. 2001).  In 
another study, Grunebach et al co-transfected primary DCs with human CD137L 
and the tumour associated antigen (TAA) HER-2/neu, and used them as APCs to 
generate HER-2/neu-specific cytotoxic T lymophocytes (CTLs).  They found that 
the presence of CD137L on the DCs enhanced the induction of TAA-specific CTL 
responses (Grunebach et al. 2005).  A third strategy employed in the whole cell 
vaccine approach is the expression of single-chain Fv fragments from an anti-
CD137 mAb on the melanoma cell line K1735.  Mice that were vaccinated with 
these transfected cells remain tumour-free when challenged with wild-type K1735 
cells.  In mice bearing established tumours, vaccination led to tumour regression 
(Ye et al. 2002; Yang et al. 2007). 
 
In another approach, T cells from tumour-bearing mice were co-stimulated with 
anti-CD137 antibodies (Abs) ex vivo, and then adoptively transferred back into the 
mice.  For the melanoma mouse model used, a 60% cure rate was achieved 
(Strome et al. 2000).  In summary, the results from these various studies clearly 
demonstrate that the engagement of CD137 on T cells can successfully enhance 











Like other members of the TNFR superfamily (Eissner et al. 2004) , the 
CD137:CD137L system is capable of bidirectional signaling.  This refers to signal 
transduction through both the receptor and its ligand when they bind to each other.  
In other words, when CD137 on T cells is engaged by its ligand on APCs, a signal 
is also transmitted through CD137L into the APCs.   This reverse signal through 
CD137L results in the activation or costimulation of APCs.  
 
In monocytes, some effects of CD137L signaling include promotion of adherence 
and secretion of proinflammatory cytokines eg TNF, IL-6, IL-8 and IL-12 
(Langstein et al. 1998).  Monocytes also display enhanced proliferation and 
endomitosis in response to CD137L signaling, as a result of increased monocyte 
colony stimulating factor (M-CSF) secretion (Langstein et al. 1999; Langstein & 
Schwarz 1999).  Recently, the presence of CD137 (which is expressed on the 
walls of inflamed blood vessels) has been shown to enhance monocyte migration.  
Therefore, CD137L-mediated signals may play a role in regulating monocyte 
extravasation, for instance at sites of inflammation (Drenkard et al. 2007).  
 
DCs respond to CD137L signals by upregulating CD11c, CD80, CD86 and major 
histocompatibility complex (MHC) class II (Kim et al. 2002), and also by 
producing more IL-6 (Futagawa et al. 2002) and IL-12 (Laderach et al. 2003).  
This indicates enhanced antigen-presenting capacities in the DCs and 





For B lymphocytes, the signal through CD137L into the cells results in increased 
proliferation and immunoglobulin secretion.  However, this is observed only in 
activated and not resting B cells.  Hence, CD137L signaling has a co-stimulatory 
rather than an activating effect on B cells (Pauly et al. 2002). On the other hand, 
in vivo data from CD137L transgenic mice show that constitutive CD137L 
expression on APCs causes a depletion of mature B cells from peripheral 
lymphoid organs and impairment of immunoglobulin synthesis.  This suggests 
that while CD137L signaling stimulates B cells initially, over-stimulation has 
deleterious effects on the cells (Zhu et al. 2001).    
 
In contrast to the stimulatory effects observed in APCs, CD137L signaling into T 
lymphocytes inhibits proliferation and induces apoptosis (Schwarz et al. 1996).  
As CD137L expression on T cells is activation-dependent (Goodwin et al. 1993), 
a possible physiological function for the protein might be to down-regulate T cell 
responses when they are no longer needed.    
 
 
Figure 2.   Bidirectional signaling involving CD137 and its ligand.  Signaling 
through CD137 into T cells leads to co-stimulation.  CD137L delivers an 







1.6  POSSIBLE ROLE OF CD137 AS A NEOANTIGEN ON CANCER      
IIIIICELLS 
 
As mentioned in Section 1.1, CD137 is expressed by certain cancer cell types.  In 
particular, CD137 was present on B cells in all the cases of CLL analysed, but in 
none of the samples of healthy B cells (personal communication, Schwarz H).  
These observations suggest that CD137 might be conferring a survival advantage 
upon tumour cells, and there are several possible explanations for how this might 
be so.  
 
First of all, CD137 might exert its effects on immune effector cells, namely 
cyCTLs) and natural killer (NK) cells, which are responsible for anti-tumour 
immune responses.  One possible mechanism involves the reverse signaling 
through CD137L into T cells, which results in T cell death.  Hence, cancer cells 
may express CD137 in order to engage CD137L on T cells, so as to induce T cell 
apoptosis and consequently, escape immuno- surveillance.  This scenario would 
be analogous to the expression of Fas ligand (FasL) by cancer cells.  In the “Fas 
counter-attack hypothesis”, FasL expressed on cancer cells is hypothesized to 
interact with Fas expressed on activated T cells, thus leading to T cell apoptosis 
(Whiteside 2007).  In the case of NK cells, any effect due to CD137 is likely to be 
indirect since NK cells do not express CD137L.   
 
The fact that CD137 facilitates monocyte migration raises the possibility of cancer 
cells expressing CD137 to recruit monocytes to the tumour site.  These monocytes 
can differentiate into macrophages, and the tumour associated macrophages can in 





signaling upregulates the expression of the anti-apoptotic proteins Bcl-XL and 
Bfl-1 (Lee et al. 2002), therefore the engagement of CD137 on cancer cells can 
potentially enhance survival and proliferation.  This likely occurs when CD137L-
expressing APCs come into contact with the cancer cells.  Anti-apoptotic proteins 
in the Bcl-2 family have oncogenic potential (Cory et al. 2003), and the 
overexpression of Bcl-XL in a breast cancer cell line resulted in increased 
resistance to chemotherapeutic drugs (Wang et al. 2005).  Because of this, it is 
possible that CD137 expression is able to protect cancer cells from drug-mediated 
cell death.  
 




Currently, studies involving CD137 as a candidate for immunotherapy have 
utilised the co-stimulatory function of CD137.  Various methods have been used 
to engage CD137 on T cells in order to generate stronger T cell responses and thus 
lead to tumour eradication (refer to Section 1.4).  As an alternative, given the role 
of CD137 as a potential neo-antigen in cancer cells, we propose that the inhibition 
of CD137 activities on CD137-expressing cancer cells can complement 
chemotherapeutic treatment.    
 
Soluble CD137 (sCD137) is present endogenously (Michel et al. 1998; Jung et al. 
2004; Furtner et al. 2005) and can be generated by alternative mRNA splicing 
(Setareh et al. 1995).  In vitro studies using murine and human systems have 
shown that sCD137 inhibits the effects of its membrane-bound counterpart.  In 





CD3 Abs (Hurtado et al. 1995), while a study using human peripheral blood 
mononuclear cells (PBMCs) showed that sCD137 levels correlated with apoptotic 
cell death (Michel & Schwarz 2000).  Thus, sCD137 might have useful 
therapeutic applications as an inhibitor of membrane-bound CD137. 
 
1.8  THERAPEUTIC APPLICATIONS OF SOLUBLE TNFRS 
 
Indeed, soluble forms of other members of the TNFR super family have already 
been proven to be effective in therapy.  Etanercept is a soluble receptor consisting 
of the TNF-binding extracellular domain of TNFR-2 fused to the Fc portion of 
human IgG1.  It binds to TNFα and β, preventing the cytokines from associating 
with cell surface TNFRs.  Since no signal transduction can occur via the soluble 
receptors, the biological activity of TNFα and β is blocked.  Etanercept is used 
clinically for the treatment of rheumatoid arthritis and several other auto-immune 
diseases (Gatto 2006).  Recently, Deng et al showed that it possible to inhibit 
TNFα activity just by targeting the pre-ligand assembly domain (PLAD) (refer to 
section 1.9 below) of TNFR1, instead of the entire extracellular domain.  In 
murine arthritis models, a soluble PLAD protein that binds to the PLAD of 
TNFR1 was successfully used to ameliorate inflammatory arthritis (Deng et al. 
2005).   
 
1.9  PLAD  
 
For TNFR1, -2 (Chan et al. 2000) and CD95 (Papoff et al. 1999; Siegel et al. 





responsible for initiating receptor trimerisation in the absence of ligand binding. 
This domain is termed PLAD, and it lies outside of ligand-binding regions of the 
receptors.  By associating with membrane-bound receptors at the PLAD, the 
addition of soluble PLAD protein prevents the formation of signaling trimers due 
to the lack of a cytoplasmic domain necessary for signaling.   
 
 
Figure 3.  A model of how soluble PLAD protein can disrupt TNFR signaling.  
Soluble PLAD protein of the TNFR associates with membrane-bound receptors at 
the PLAD domain.  This prevents the assembly of receptor trimers and thus blocks 
signal transduction (Deng et al. 2005).  Reprinted with permission from Lenardo, 
M.   
 
 
Targeting the PLAD for the inhibition of TNF-mediated signals can be an 
attractive alternative to current methods such as anti-TNF Abs and soluble 
recombinant receptor proteins, each of which has its own disadvantages (Chan 
2000).  Currently, it is unknown if CD137 also undergoes pre-ligand assembly.  In 
view of the potential advantages of targeting PLAD for therapeutic applications, it 










1.10 OBJECTIVES OF STUDY 
 
The specific objectives of this study are: 
a. to generate cell lines with stable CD137 expression via transfection, 
followed by the characterization of these cell lines. 
b. to investigate whether CD137 expression protects cancer cells against 
lymphokine activated killer (LAK) cells and chemotherapeutic drugs. 
c. To investigate whether CD137 expression on cancer cells enhances 
monocyte migration to the tumour site. 
d. to determine if sCD137 associates with membrane-bound CD137, and to 





CHAPTER 2  MATERIALS AND METHODS 
 
All materials were purchased from Sigma-Aldrich (St Louis, MO) unless 
otherwise stated. 
 
2.1  CELL LINES  
 
The MCF7 breast adenocarcinoma cell line was a gift from Dr Shen Shali 
(Department of Physiology, NUS).  MM5 is a multiple myeloma cell line and was 
obtained from Dr Charles Gullo (Department of Clinical Research, Singapore 
General Hospital).  These cells were routinely cultured in DMEM + 10% heat-
inactivated fetal bovine serum (FBS), henceforth referred to as DMEM-10 (refer 
to Appendix I).  The monocytic cell line THP-1 was obtained from Dr Lim Yaw 
Chyn (Department of Pathology, NUS), and were maintained in RPMI 1640 + 
10% heat-inactivated FBS, henceforth referred to as RPMI-10 (refer to Appendix 
I).  Cells were passaged every 2-3 days, with MCF7 cells being detached using 
either trypsin-EDTA (Gibco Invitrogen, Carlsbad, CA) or 10 mM EDTA in 
phosphate buffered saline (PBS) (refer to Appendix I).   All cells were kept in a 













Table 1.  List of antibodies used. 
Antibody Clone Source 
Mouse anti-human CD137 (PE 
conjugated) 4B4-1 
BD Pharmingen (Franklin 
Lakes, NJ) 
Mouse anti-human CD137L (PE 
conjugated) 5F4 Biolegend (San Diego, CA) 




Sigma-Aldrich (St Louis, 
MO) 
Mouse anti-human CD137  M127 BD Pharmingen (Franklin Lakes, NJ) 
Mouse anti-human CD137 (Biotin 
conjugated) 4B4-1 
BD Pharmingen (Franklin 
Lakes, NJ) 
Mouse anti-Flag  M2 Sigma-Aldrich (St Louis, MO) 
Polyclonal rabbit anti-mouse Ig 
(FITC conjugated)  -  Dako (Denmark) 
Goat F(ab')2 Anti-Human IgG (RPE 
conjugated)  -  
Caltag Laboratories 
(Burlingame, CA) 
Mouse anti-human MICA/B (PE 
conjugated) 6D4 eBioscience (San Diego, CA) 
 
 
2.3  GENERATION OF STABLE, CD137-EXPRESSING MCF7 CELL    
IIIIILINES 
 
2.3.1  Plasmids  
 
The plasmid CMV-ILA-SEN (CIS) was constructed by inserting full length 
human CD137 cDNA into the eukaryotic expression vector pcDNA3 (Invitrogen, 







2.3.2  Transfection of MCF7 cells 
 
One day prior to transfection, 5 x 104 cells/well were plated in a 24-well plate 
(Nunc, Rosklide, Denmark).  Transfection was performed using Lipofectamine™ 
2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.  A 
DNA: Lipofectamine™ ratio of 1 µg : 1 µl was used.  Cells were transfected 
either with the plasmid CIS, or with the empty vector as control.   
 
2.3.3  Selection of stably-transfected clones 
 
48 h post-transfection, the transfected cells were transferred to 15 cm tissue 
culture dishes (BD Falcon™, Franklin Lakes, NJ), at a seeding density of 2.5 x 
105 cells/dish.  Subsequently, the cells were maintained in DMEM-10 
supplemented with 800 µg/ml Geneticin® (Gibco-Invitrogen, Carlsbad, CA) for 
approximately 14 days, with medium changes every 3-4 days.   
 
Stable clones were picked when visible colonies of cells have formed in the 
culture dish.  Before picking the colonies, 24-well plates containing 400 µl of 
selection medium (DMEM-10 + 800ul/ml Geneticin®) per well were prepared.  
Most of the medium was then aspirated from the culture dish containing the 
clones.  Using a yellow pipette tip containing 100 µl of selection medium, the 
colony of interest was gently scraped, flushed with some medium and then 
aspirated.  The cells were transferred to a well in one of the 24-well plates and the 
process was repeated.  These cells were maintained with medium changes every 





Clones transfected with CD137 were screened for CD137 expression via flow 
cytometry when they reached confluency (1-2 weeks after picking).  Cells were 
washed twice with PBS and then detached using 10 mM EDTA in PBS.  2 x 105 
cells were stained with 50 µl of PE-conjugated anti-human CD137 (1:20) or with 
mouse IgG1 isotype control (1:100) mAbs for 30 min at room temperature.  The 
antibodies were diluted in FACS buffer (PBS containing 0.5% FBS and 0.02% 
NaN3) (refer to Appendix II).  After staining, cells were washed thrice with FACS 
buffer and resuspended in 500 µl of buffer for analysis using Cyan™ flow 
cytometer (DakoCytomation, Denmark).  Results were analysed with Summit 4.2 
software (DakoCytomation, Denmark).  The clones which expressed the desired 
levels of CD137 were subsequently expanded and named as ‘MCF7/hCD137-
clone number’.  The expression levels of CD137 on the clones used for the 
experiments were also monitored by flow cytometry on a weekly basis. 
 
Clones transfected with the empty vector were expanded when they reached 
confluency (1-2 weeks after picking) and named as ‘MCF7/pcDNA3-clone 
number’.  MCF7/pcDNA3 and MCF7/pcDNA3A are instances of variants 
transfected with the empty vector pcDNA3. 
 
2.4  MEASUREMENT OF CELL PROLIFERATION VIA 3H-THYMIDINE                              
IINCORPORATION 
 
Cells were pulsed overnight with 0.5 µCi of 3H-thymidine (diluted in medium) at 
37ºC. Subsequently, the cells were harvested onto UniFilter plates (Perkin Elmer, 
Waltham, MA) using the MicroMate 196 cell harvester (Perkin Elmer, Waltham, 





MicroScint™ solution (Perkin Elmer, Waltham, MA) were added per well.  
Lastly, radioactivity was measured using the TopCount liquid scintillation 
analyzer (Packard Instrument, Meridien, CT). 
 




Buffy coats from healthy donors were obtained from Blood Donation Centre, 
National University Hospital.  PBMCs were isolated by gradient centrifugation 
using Histopaque®-1077 according to manufacturer’s protocol.  Red blood cells 
(RBCs) were removed by incubating the PBMCs with RBC lysis buffer (refer to 
Appendix I) for 10 min at room temperature, followed by 2 washes with 2 mM 
EDTA in PBS.  The cells were then cultured in RPMI-10 supplemented with 100 
U/ml penicillin and 100 µg/ml streptomycin (Gibco Invitrogen, Carlsbad, CA).      
 
2.6  LYMPHOKINE ACTIVATED KILLER (LAK) CELLS ASSAY 
 
1 day prior to the assay, 2 x 104 target cells/well were plated in flat-bottomed 96 
well plates (Nunc, Rosklide, Denmark).  The next day, supernatants were 
aspirated and cells were washed once with PBS.  For the fluorescent labeling of 
target cells, 50 µl of Calcein AM (Molecular Probes, Invitrogen, Carlsbad, CA), 
diluted 100x in PBS + 10% FBS (PBSF) were added to each well.  Following a 30 
min incubation at 37ºC, cells were washed once with PBS, and 100 µl of PBSF 






LAK cells were prepared by culturing freshly isolated PBMCs at an initial cell 
density of 2 x 106 cells/ml, in the presence of 1000U/ml of IL-2 (Proleukin) 
(Norvatis Pharmaceuticals, East Hanover, NJ), for 3 days.  On the day of the 
assay, the non-adherent cells were harvested, washed once with PBS, and 
resuspended in PBSF at the desired cell concentrations.  100 µl of LAK cells/well 
were then added to the labeled target cells.  For measuring the spontaneous and 
total lysis of target cells, 100 µl of PBSF or lysis buffer (refer to Appendix I) 
instead of LAK cells were added respectively.  Cells were incubated for 4 h at 
37ºC, after which the plates were centrifugated at 1500 rpm for 10 min.  Finally, 
100 µl of supernatant from each well were transferred to a flat-bottomed 96 well 
black plate, and fluorescence was measured at Ex485/Em535 using a fluorescence 
plate reader.  The percentage of target cell cytotoxicity was calculated according 
to the formula: % cytotoxicity = 100 x (sample lysis – spontaneous lysis)/ (total 
lysis – spontaneous lysis). 
 
2.7  FLOW CYTOMETRIC ANALYSIS OF CELL SURFACE NATURAL  




2 x 105 cells were incubated with 50 µl of recombinant NKG2D-Fc protein (R & 
D Systems, NE Minneapolis, MN), at a concentration of 1 µg/ml, for 30 min at 
room temperature.  After 3 washes with FACS buffer, the cells were stained with 
PE-conjugated anti-human IgG (1:50) for 30 min at room temperature.  For the 
detection of MICA/B, 2 x 105 cells were incubated with 50 µl of PE-conjugated 
anti-MICA/B mAbs (1:10) for 30 min at room temperature.  All samples were 






2.8  COATING OF CD137-FC AND FC PROTEIN 
 
Recombinant human CD137 protein was prepared as a fusion protein tagged with 
the Fc portion of human IgG1 molecule and human IgG Fc protein (Chemicon 
Millipore, Billerica, MA) was used as a control in all experiments.  96-well plates 
were coated with 50 µl of CD137-Fc or Fc protein diluted in PBS to a final 
concentration of 10 µg/ml (unless otherwise stated) per well.  Plates were 
incubated at 37ºC for 2 h and the wells were washed 3 times with PBS before cells 
were added.   
 
2.9  ADHESION ASSAY 
 
Monocytes were isolated from PBMCs (refer to Section 2.5) via magnetic cell 
sorting using the Monocyte Isolation Kit II (Miltenyi, Germany) according to the 
manufacturer’s instructions.  In brief, non-monocytes were indirectly magnetically 
labeled with a cocktail of monoclonal antibodies, and were depleted by retention 
in a MACS® column (Miltenyi, Germany) in a magnetic field.  After the 
monocytes had been collected, the monocyte-depleted fraction of total PBMCs 
was harvested by flushing them out of the column.   
 
Total PBMCs, monocytes and monocyte-depleted PBMCs were labeled with 
Calcein AM (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions.  Cells were then counted and resuspended in RPMI-10 supplemented 






One day prior to the assay, MCF7 variants were seeded at an initial density of 1 x 
104 cells per well in flat-bottomed 96 well plates.  The next day, media were 
aspirated from the wells, followed by 3 washes with PBS.  100 µl of 2% (w/v) 
paraformaldehyde in PBS (PFA) were added to each well and the cell monolayers 
were fixed at 4ºC for 1 h.  This was followed by 5 washes with 100 µl of PBS, 
after which 100 µl of labeled total PBMCs, monocytes or monocyte-depleted 
PBMCs were added per well.  
 
At specific time points, medium was aspirated and wells were washed 3 times 
with PBS to remove cells which did not adhere to the base of the wells.  Wells 
were incubated with 100 µl of lysis buffer (refer to Appendix I) at room 
temperature for 30 min.  80 µl from each well were transferred to a flat-bottomed 
96 well black plate, and fluorescence was measured at Ex485/Em535 using a 
fluorescence plate reader. 
 
2.10  MEASUREMENT OF DRUG-INDUCED CYTOTOXICITY VIA 
LACTATE DEHYDROGENASE (LDH) RELEASE 
 
 
1 x 104 cells per well were plated in flat-bottomed 96-well plates.  The next day, 
supernatants were aspirated and 100 µl of LDH assay medium (DMEM + 1% 
FBS) were aliquoted into each well.  Camptothecin (CPT) was diluted in assay 
medium through a series of 2-fold dilutions.  For each concentration of CPT, 100 
µl were added per well in triplicates.  Instead of CPT, 100 µl of either assay 
medium or 2% Triton X-100 (Bio-Rad, Hercules, CA) in assay medium were 





48 h at 37ºC, after which the supernatants were harvested and assayed for LDH 
activity using the Cytotoxicity Detection Kit (LDH) (Roche, Mannheim, 
Germany) according to the manufacturer’s protocol. 
 
2.11  FIXATION OF MCF7 VARIANTS 
 
Cells were detached with 10 mM EDTA in PBS and incubated with 2% PFA for 2 
h on ice.  After fixation, cells were washed thrice, with 10 ml PBS each time.  The 
cells were then counted, resuspended in medium and aliquoted into wells. 
 





MM5 or THP-1 cells were added to U-bottomed 96-well plates (Greiner Bio-One, 
Germany) at 5 x 104 cells per well in 100 µl of their respective media. These cells 
were cultured for 24 h either in CD137-Fc or Fc coated wells (refer to Section 
2.8), or with an equal number of fixed MCF7 variant cells (refer to Section 2.11).  
Supernatants were then harvested and stored at -20 ºC until analysis.   
 
2.13  IL-8 SANDWICH ELISA   
 
Levels of IL-8 present in supernatants (refer to Section 2.12) were assayed using 
the IL-8 DuoSet® ELISA Development System (R & D Systems, NE 
Minneapolis, MN) according to the manufacturer’s protocol.  For all samples, 






2.14  CULTURE OF PBMCS IN THE PRESENCE OF CD137 
 
PBMCs were added to U-bottomed 96-well plates at 5 x 104 cells per well in 100 
µl of medium supplemented with various concentrations of anti-CD3 antibody.  
These cells were cultured for 4 days either in CD137-Fc or Fc coated wells (refer 
to Section 2.8), or with an equal number of fixed MCF7 variant cells.  
Subsequently, PBMC proliferation was measured via the 3H-thymidine 
incorporation assay (refer to Section 2.4), with each condition being performed in 
triplicates. 
 
2.15  LIVE CELL ELISA 
 
2.15.1  MCF7 variants in suspension 
 
Wells were coated with 50 µl of capture antibody (anti-human CD137, clone 
M127, diluted in PBS to 2 µg/ml) for 2 h at 37°C, and then blocked overnight 
with blocking buffer (refer to Appendix II) at 4°C.  100 µl of cells resuspended in 
DMEM-10 to various cell densities were added to the wells for 2 h at 37°C, and a 
standard curve ranging from 2.5 – 160 ng/ml was generated by 2-fold serial 
dilutions of CD137-Fc protein in DMEM-10.  50 µl of the biotin-conjugated anti-
human CD137 antibody (diluted in blocking buffer to 0.5µg/ml) were added to 
each well for 2 h at 37°C as detection antibody.  This was followed by 50µl of 
Streptavidin-HRP (R & D Systems, NE Minneapolis, MN) (1:200 in blocking 
buffer, 20 min, room temperature) and 100 µl of TMB substrate (20 min, room 





with 50 µl of 2N H2SO4.  The contents of the wells were transferred to a new plate 
before the absorbance was measured at 450 nm. Wells were washed 3 times with 
PBS + 0.05% Tween-20 (Bio-Rad, Hercules, CA) (PBST) (refer to Appendix II) 
in between steps, except after the addition of substrate solution.   
 
2.15.2 MCF7 variants in monolayers 
 
One day prior to the assay, cells were plate in flat-bottomed 96 well plates at 
various cell densities.  On the day of the assay, a standard curve ranging from 
0.625 – 40 ng/ml was generated by 2-fold serial dilutions of CD137-Fc protein in 
PBS and incubation at 37°C for 2 h.  Wells were then blocked with 150 µl of 
blocking buffer for 2 h at 37°C.  This was followed by incubation with 
biotinylated anti-CD137, streptavidin-HRP, TMB substrate, and the addition of 
H2SO4 as detailed in Section 2.15.1.  The contents of the wells were transferred to 
a new plate before the absorbance was measured at 450 nm. Wells were washed 3 
times with PBST in between steps, except after the addition of substrate solution.   
 
2.16  ELUCIDATION OF PLAD IN CD137 
 
2.16.1  Transfection of MCF7 cells with full length and soluble CD137 
The CD137-without transmembrane (CD137-wotm) plasmid was constructed by 
cloning the extracellular domain of human CD137, which was flanked by an IgGκ 






The CD137-PLAD plasmid was constructed by cloning the extracellular domain 
of human CD137, which was flanked by an IgGκ signal peptide sequence, and the 
His- and Flag tags at the N-terminus, into the pCDNA3.1 /V5-His-TOPO vector 
(Invitrogen, Carlsbad, CA).   
 
Transfection was performed as mentioned in Section 2.4.1 according to the 
conditions listed in Table 2 using the plasmids described above.  The plasmid 
pcDNA3 was included such that the same amount of DNA (2 µg) was transfected 
in all the conditions.  48 h post transfection, supernatants and cells were harvested 
for ELISA and flow cytometry, respectively.   
 
 
Table 2.  Conditions used for the transfection of MCF7 with full length and 
soluble CD137.  
Condition Plasmid Amount (µg) 
pcDNA3 2 pcDNA3 only 
  
CIS 0.4 










PLAD 1.6 flCD137 + sCD137 
    
 
2.16.2  Flow cytometry 
 
Cells were stained for surface CD137 expression as mentioned in Section 2.4.2.  





of either anti-Flag mAb or mouse IgG isotype control.  Both antibodies were 
diluted in binding buffer (refer to Appendix II) to a final concentration of 1 µg/ml.  
Cells were washed with FACS buffer, and 50 µl of rabbit anti-mouse IgG (diluted 
1:40 in FACS buffer) were added.  After washing, cells were stained with PE 
conjugated anti-human CD137 before analysis.  All incubations with antibodies 
were performed at room temperature for 20 min.    
 
2.16.3  Sandwich ELISA for sCD137 
 
Wells were coated with 50 µl of capture antibody (anti-human CD137, clone 
M127, diluted in PBS to 2 µg/ml) for 2 h at 37°C, and then blocked overnight 
with blocking buffer (refer to Appendix II) at 4°C.  50 µl of sample were added 
per well for 1 h at 37°C and a standard curve ranging from 3.9 – 125 ng/ml was 
generated by 2-fold serial dilutions of CD137-Fc protein in blocking buffer.  50 µl 
of the biotin-conjugated anti-human CD137 antibody (diluted in blocking buffer 
to 0.5µg/ml) were added to each well for 1 h at 37°C as detection antibody.  This 
was followed by 100 µl of Extravidin-AP (1:10,000 in PBS, 30 min, room 
temperature) and 100 µl of pNPP liquid substrate (20 min, room temperature, in 
the dark).  Finally, the reaction was stopped with 25 µl of 3N NaOH and the 
absorbance was measured at 405 nm. Wells were washed 3 times with PBST in 









CD137 is expressed by certain cancer cells such as Reed Sternberg cells in 
Hodgkin’s lymphoma (Gruss et al. 1996a; Gruss et al. 1996b), CLL (personal 
communication, H. Schwarz), osteosarcoma (Lisignoli et al. 1998),  
rhabdomyosarcoma (personal communication, H. Schwarz) and pancreatic cancer 
(Ringel et al. 2001).  In the case of CLL, CD137 was present on B cells in 14 out 
of 14 patient samples tested, but on none of the B cells from healthy donors 
(personal communication, H. Schwarz).  There appears to be a correlation 
between malignancy and CD137 expression in this case, hence it was 
hypothesized that cancer cells may express CD137 as a neo-antigen to gain certain 
survival advantages. 
 
Due to the bidirectional nature of CD137:CD137L signaling, there are two general 
aspects in which the role of CD137 as a cancer neo-antigen can be investigated.  
When CD137 on cancer cells engage CD137L which are expressed on APCs and 
activated T cells, both signaling into the CD137L-expressing cells, as well as 
signaling via CD137 into the cancer cells may potentially be responsible for 
conferring a survival advantage upon cancer cells.  As a result, increased T cell 
apoptosis (Schwarz et al. 1996) and/or enhanced monocyte migration (Drenkard 
et al. 2007) to the tumour site might be observed in the former scenario, while the 
latter might lead to upregulation of anti-apoptotic proteins (Lee et al. 2002) in 







3.1 GENERATION OF STABLE, CD137-EXPRESSING CELL LINES 
 
To investigate the potential role of CD137 in tumour progression, stable cell lines 
that overexpress CD137 were generated.  MCF7 is a human breast cancer cell line 
that expresses neither CD137 nor CD137L (Figure 4).  Cells were transfected with 
a plasmid containing the full length human CD137 cDNA (CIS) or with the empty 
vector (pcDNA3).  These plasmids contain a neomycin resistance gene, and stably 
transfected clones were selected by resistance against the antibiotic Geneticin®. 
To determine the dosage required, Geneticin® was titrated and added to 
untransfected MCF7 cells at various concentrations.  It was found that Geneticin® 
at a concentration of 800 µg/ml was able to cause massive cell death in MCF7 
cells within 5 days, with no cells being alive by day 14 (data not shown).        
 
    A                                                              B 
     
Figure 4.  Wild type MCF7 cells express neither CD137 nor CD137L.  Cells 
were stained with PE-conjugated α-CD137 mAb (A) or α-CD137L mAb (B), and 
analysed by flow cytometry.  Numbers denote % of CD137- or CD137L- positive 
cells. Red histograms: isotype control; green histograms: α-CD137 mAb in (A) 
and α-CD137L mAb in (B).  
 
Expression of CD137 by MCF7/hCD137 variants was confirmed by flow 
cytometry (Figure 5).  The variants MCF7/hCD137-3 and -33 expressed CD137 at 







(Figure 5C and D).  MCF7/hCD137-15 cells had a moderate level of CD137 
expression (44.9% CD137-positive cells, Figure 5E) while MCF7/hCD137-52 
cells expressed CD137 at a low level (26.7% CD137-positive cells, Figure 5F).  
Variants transfected with the empty vector (i.e. MCF7/pcDNA3 and 
MCF7/pcDNA3A) expressed no CD137 (Figures 5A and 5B) and were included 
in subsequent experiments as negative controls.  Weekly flow cytometric analyses 
showed that the levels of CD137 expression on the variants remained generally 
constant (data not shown).  Furthermore, there were no observable differences in 
the morphologies of all the variants which were established (data not shown).   
 
Proliferation rates of the MCF7 variants were determined by 3H-thymidine 
incorporation and were expressed relative to that of MCF7/pcDNA3 cells (Figure 
6).  The expression of CD137 does not appear to affect the proliferation of the 
cells since there were no significant differences in proliferation rate among the 
different MCF7 variants.       
 
In summary, wild type MCF7 cells were transfected with a plasmid containing full 
length human CD137 to generate CD137-expressing MCF7 variants.  Following 
antibiotic selection, four variants with varying levels of CD137 expression (as 
determined by flow cytometry) were established.  Finally, these variants do not 
differ significantly from those transfected with the empty vector in terms of 









   A.  MCF7/pcDNA3                                      B. MCF7/pcDNA3A  
      
C. MCF7/hCD137-3                                    D.  MCF7/hCD137-33 
    
  E.  MCF7/hCD137-15                                    F.  MCF7/hCD137-52                        
    
Figure 5.  Expression of CD137 on MCF7 variants.  Cells were stained with 
PE-conjugated α-CD137 mAb and analysed by flow cytometry.  Numbers denote 
% of CD137-positive cells.  Red histograms: isotype control; green histograms: 
α-CD137 mAb.  








































Figure 6.  CD137 expression on MCF7 variants does not affect cell 
proliferation.  Cells were plated in a 96 well plate at a density of 1 x 104 
cells/well.  After the cells had adhered to the plate, they were serum-starved 
overnight.  The next day, cells were once again cultured in the presence of serum, 
and then pulsed with 3H-thymidine as detailed in Section 2.4.  Means of three 






3.2  CD137 EXPRESSION AND PROTECTION AGAINST LYMPHOKINE  
___ACTIVATED KILLER (LAK) CELLS-MEDIATED CYTOTOXICITY 
 
 
To determine if CD137 expression protects cancer cells from being eliminated by 
cytolytic immune cells, in vitro cytotoxicity assays were performed using LAK 
cells and MCF7 variants as effector and target cells respectively. LAK cells refer 
to cytotoxic effectors generated by culturing PBMCs in the presence of IL-2 
(Grimm & Wilson 1985).  These cells are heterogeneous in phenotype, consisting 
mainly of NK cells (CD3-CD5-CD56+CD16+), as well as a small sub-population 
of T cells (CD3+CD56+) (Schmidt-Wolf et al. 1997).  As LAK cells can mediate 
non-MHC-restricted cytotoxicity against cancer cells, they have been widely 
studied for use in human adoptive immunotherapy.   
 
In the cytotoxicity assay, target cells (i.e MCF7 variants) were labeled with 
Calcein AM, a membrane-permeant dye that is converted to the fluorescent 
calcein by intracellular esterases.  Subsequently, they were incubated with LAK 
cells at different effector to target (E:T) ratios. Upon lysis, target cells released 
calcein into the supernatant. Therefore, the fluorescence intensity of the 
supernatant is a measurement of the extent of target cell cytotoxicity.     
 
At the E:T ratio of 10:1, less cell death was observed in the four CD137-
expressing MCF7 variants than in MCF7/pcDNA3 cells (Table 3 and Figure 7).  
The amount of CD137 expressed by the cells did not appear to correlate with 
susceptibility to LAK cells-induced cytotoxicity, since there was no significant 
difference in the percentages of cell death among the different MCF7/hCD137 





At the E:T ratio of 25:1, CD137-expressing cells were still less susceptible to 
killing by LAK cells, with the exception of MCF7/hCD137-33 cells, which did 
not differ significantly from the empty vector-transfected variant in terms of 
percentage of cell death.  At the remaining E:T ratio of 50:1, there was no 
significant difference in cell death between all the variants.   
 
Table 3.   CD137-expressing cells were less susceptible to LAK cells-induced cytotoxicity. 
Means ± standard deviation (SD) of triplicates are depicted.  Similar results were obtained in three 
independent experiments. 











10:1 55.4 ± 6.1 40.5 ± 4.5 39.4 ± 5.9 34.9 ± 4.0 32.9 ± 6.1 
25:1 85.8 ± 3.7 67.5 ± 8.9 73.4 ± 7.7 68.4 ± 1.3 66.8 ± 2.3 
50:1 82.8 ±  15.8 76.0 ±  1.9 84.0 ±  5.6 96.0 ±  10.8 102.7 ±  3.7  
 
To verify the above results, another empty-vector transfected variant, 
MCF7/pcDNA3A was included in the experiment.  At the first E:T ratio, the 
MCF7/pcDNA3A was less resistant to LAK cell-mediated killing than 
MCF7/hCD137-15 and -52 cells, but not MCF7/hCD137-3 and -33 cells (Table 4 
and Figure 8).  However, at the E:T ratio of 25:1, more cell death was observed in 
all the CD137-expressing variants than in MCF7/pcDNA3A cells, as opposed to 
the trend observed with the other empty vector-transfected variant, 































Figure 7.  CD137-expressing cells were less susceptible to LAK cells-induced 
cytotoxicity.  Means ± SD of triplicates are depicted.  Similar results were 
obtained in three independent experiments.     
 
Table 4.   CD137-expressing cells were more susceptible to LAK cells-induced cytotoxicity when 
compared with a different empty vector-transfected clone.  Means ± SD of triplicates are 
depicted.  Similar results were obtained in three independent experiments.     











10:1 49.0 ± 4.8 40.5 ± 4.5 39.4 ± 5.9 34.9 ± 4.0 32.9 ± 6.1 
25:1 39.6 ± 9.5 67.5 ± 8.8 73.4 ± 7.7 68.4 ± 1.3 66.8 ± 2.3 
50:1 68.4 ±  4.8 76.0 ±  1.9 84.0 ±  5.6 96.0 ±  10.8 102.7 ±  3.7  
 
At the E:T ratio of 50:1, MCF7/hCD137-33, -15 and -52 cells exhibited higher 





difference in cytotoxicity between MCF7/hCD137-3 cells and the empty vector-





























Figure 8.  CD137-expressing cells were more susceptible to LAK cells-
induced cytotoxicity when compared with a different empty vector-
transfected clone.  Means ± SD of triplicates are depicted.  Similar results 
were obtained in three independent experiments.     
 
 
To summarise, different results were observed when the CD137-expressing 
variants were compared with different empty vector-transfected variants.  Relative 
to MCF7/pcDNA3 cells, it appeared that CD137 expression did protect the cells 
from being killed by LAK cells.  However, relative to the other empty vector-





contrasting results, it was concluded that it remains uncertain whether CD137 
plays a role in protecting against LAK cells-mediated cytotoxicity. 
 
Concurrently, we sought to investigate the potential mechanisms by which CD137 
expression might protect cancer cells from LAK cells-mediated cytotoxicity.  
Since the cytolytic effect of LAK cells is mainly attributed to NK cells, we looked 
into the possible ways in which NK cells-mediated cytotoxicity might be affected.  
This led us investigate whether the natural killer group 2D (NKG2D) receptor is 
involved. 
 
NKG2D is cell surface receptor expressed on NK cells and CD8+ T lymphocytes 
(Coudert & Held 2006). Upon engagement with its ligands, NKG2D delivers an 
activating signal into NK cells and a co-stimulatory signal into T cells.  This 
results in cytotoxic lysis of the cell expressing the NKG2D ligand (NKG2DL) 
(Jamieson et al. 2002).  NKG2D interacts with a number of ligands such as MHC 
class I chain-related A and B proteins (MICA/B) (Bauer et al. 1999) and the UL 
16 binding proteins (ULBPs) (Cosman et al. 2001).  Most healthy tissues do not 
normally express NKG2DLs, but there are some exceptions to this general rule, 
such as certain activated immune cells and intestinal epithelial cells (Mistry & 
O'callaghan 2007).  Many studies have found that NKG2DLs are upregulated 
under conditions of stress such as bacterial (Vankayalapati et al. 2005) and viral 
infection (Rolle et al. 2003), heat shock treatment (Groh et al. 1996) and 
genotoxic stress (Gasser et al. 2005).  In addition, NKG2DLs are also 
constitutively expressed by many tumours, although expression levels decrease 






 Given the function of NKG2DLs in activating NK cells, we hypothesized that 
CD137 expression might cause the down-regulation of NKG2DL on cancer cells, 
leading to a reduction in NK cell-mediated cytotoxicity.  To investigate this 
possibility, cell surface expression of NKG2DLs on MCF7 variants was detected 
using (a) recombinant NKG2D-Fc protein, followed by PE-conjugated anti-human 
Fc Ab, and (b) anti-MICA/B mAb.  Cells were also separately stained with anti-
CD137 mAb to determine if the expression of CD137 correlates with that of 
NKG2DLs.    
 
Flow cytometric analysis of MCF7 variants showed that, while both empty vector- 
transfected variants expressed similar levels of NKG2DLs (7.4% NKG2DLs-
positive cells in MCF7/pcDNA3 cells and 8.9% NKG2DLs- positive cells in 
MCF7/pcDNA3A cells), there was an approximately 5-fold difference in 
NKG2DLs expression between the different CD137-expressing variants (Figure 
9).  The two variants with higher CD137 expression, MCF7/hCD137-3 and -33 
cells had lower levels of NKG2DLs expression (3.0 and 3.2% of NKG2DLs-
positive cells respectively) than the other two variants which expressed less 
CD137.  For MCF7/hCD137-15 and -52 cells, 15.2% and 13.1% of the cells 
expressed NKG2DLs, respectively.  CD137 and NKG2DLs levels do not appear 
to correlate with each other.  This is because, although variants that expressed 
more CD137 (i.e. MCF7/hCD137-3 and -33) expressed less NKG2DLs, non-
CD137-expressing variants (i.e. MCF7/pcDNA3 and MCF7/pcDNA3A) did not 
have the highest level of NKG2DLs expression.  Using a monoclonal antibody 





MICA/B expression was observed among the MCF7 variants.  As is the case for 
NKG2DLs, MICA/B and CD137 expression do not appear to be correlated.    
 
Figure 9 (on the next page).  Expression of CD137, NKG2DLs and MICA/B 
on MCF7 variants.  Numbers denote % of CD137-, NKG2DLs- or MICA/B- 
positive cells. Red histograms: isotype control; green histograms: α-CD137 mAb, 
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3.3  CD137 EXPRESSION AND THE PROMOTION OF MONOCYTE 
____ADHESION  
 
CD137 has been reported to facilitate monocyte migration (Drenkard et al. 2007), a 
finding which led to the hypothesis that the role of CD137 as a cancer neoantigen 
may be to enhance monocyte recruitment to the tumour site.  These monocytes may 
differentiate into M2 macrophages which contribute to tumour angiogenesis by 
secreting cytokines (eg. vascular endothelial growth factor) and proteases (eg matrix 
metalloproteinases) (Schmid & Varner 2006).  Since CD137 is able to facilitate 
monocyte migration, it is highly plausible that CD137 also induces monocytes to 
adhere more strongly because adhesion is a prerequisite for migration.  Indeed, 
primary monocytes cultured in CD137-Fc-coated wells have been observed to adhere 
more strongly to the wells as compared to Fc-coated wells (Langstein et al. 1998).  
Consequently, an assay which utilizes this property of CD137 was designed to 
investigate whether MCF7/hCD137 variants were able to promote adhesion in 
monocytes. 
 
In brief, fluorescently labeled total PBMCs (of which approximately 10% comprise 
monocytes) were added to fixed monolayers of MCF7 variants.  For this set of 
experiments, two MCF7/hCD137 variants, one with high CD137 expression 
(MCF7/hCD137-33) and the other with low CD137 expression (MCF7/hCD137-52) 
were used to determine if the ability to induce PBMCs adhesion was correlated with 
the amount of cell surface CD137. MCF7/pcDNA3 and MCF7/pcDNA3A cells 





as positive controls, with Fc-coated wells serving as a negative control for any effect 
that might have been caused by the Fc portion of the recombinant CD137-Fc protein.  
At specific time points, the PBMCs were aspirated and unattached cells were 
removed by washing.  Cells remaining in the wells were lysed, and the fluorescence 
intensities of the lysates (given in relative fluorescence units or RFUs) indicated the 
degree to which total PBMCs adhered to the different surfaces. 
 
Figure 10 shows that total PBMCs adhered more strongly to CD137-Fc-coated than to 
Fc-coated surfaces.  This effect was consistently observed when the cells were 
allowed to adhere for 30 min or more.  The difference in the degree of cell adhesion 
between CD137-Fc- and Fc-coated surfaces increased with increasing incubation 
times, ranging from ~18% at the 30 min time point to ~54% at the 4 h time point.  
Therefore, these results show that this is a feasible system for the quantification of 
PBMC adhesion in response to CD137.   
 
For the MCF7 variants, there were no significant differences between the variants 
used, with a few exceptions.  First of all, comparing between the two control variants 
MCF7/pcDNA3 and MCF7/pcDNA3A, there was a difference only at the 2 h time 
point, in which ~32% more adhesion was observed in MCF7/pcDNA3A wells.  Thus, 
it was concluded that in general, there was no difference in the abilities of both 






Although CD137-Fc enhanced PBMCs adhesion, such an effect was not detected with 
the two CD137-expressing variants used.  MCF7/hCD137-33 cells promoted PBMC 
adhesion by ~56% as compared to MCF7/pcDNA3 cells when the PBMCs were 
added for 1 h, but no differences were observed for the remaining timepoints.  
Overall, there appears to be no consistent correlation between CD137 expression on 
MCF7 cells and the degree of PBMCs adhesion. 



































        
Figure 10.  CD137-Fc, but not CD137-expressing cells, promotes adhesion of total 
PBMCs.  Means ± SD of triplicates are depicted.  Similar results were observed in two 
independent experiments. * denotes p < 0.05 as compared to Fc, ** denotes p < 0.05 as 




To verify the results, the above experiment was repeated using monocytes instead of 
total PBMCs.  Similar to what was observed in PBMCs, monocytes adhered more 
strongly to CD137-Fc than Fc-coated surfaces (Figure 11).  However, the difference 





than that seen with PBMCs.  After 30, 60, and 120 min of incubation with monocytes, 
CD137-Fc-coated wells induced ~30.5, 11.2 and 11.5 % more adhesion than Fc-
coated wells.  In addition, the difference in the degree of adhesion did not increase 
with increasing incubation times.  Among the MCF7 variants, there was no 
significant difference in their abilities to induce monocyte adhesion.  


































Figure 11.  CD137-Fc, but not CD137-expressing cells, promotes adhesion of 
primary monocytes.  Means ± SD of triplicates are depicted.  Similar results were 
observed in two independent experiments. * denotes p < 0.05 as compared to Fc. 
 
 
When PBMCs that were depleted of monocytes were used for the above experiment, 
there was no significant difference between the degree of adhesion induced by 
CD137-Fc and Fc (Figure 12).  This shows that the induction of cell adhesion 






        
























Figure 12.  CD137-Fc does not promote the adhesion of monocyte-depleted 
PBMCs.  Means ± SD of triplicates are depicted.  Similar results were observed in two 
independent experiments.  
 
 
Lastly, the concentration of protein used for coating the wells in this experimental 
setup was titrated to determine the amount of CD137-Fc required for the induction of 
adhesion in PBMCs.  Prior to that, it was necessary to determine how much and what 
percentage of CD137-Fc was actually coated onto the wells when coating solutions of 
different concentrations were used.  Consequently, the coating solution was harvested 
after coating and assayed for CD137 content via sandwich ELISA.  It was found that 
negligible levels of CD137 remained in the coating solutions even at the highest 
protein concentration used, which was 10 µg/ml (data not shown).  This proves that 
virtually all of the CD137-Fc that was originally present in the coating solution had 





Next, total PBMCs were added to wells coated with different amounts of CD137-Fc 
and Fc and the experiment was performed as detailed above.  CD137-Fc was able to 
induce adhesion in PBMCs at all the three concentrations used (Figure 13).   
 
In summary, PBMCs adhered more strongly in the presence of CD137-Fc.  This 
effect was shown to be specific to monocytes, since PBMCs depleted of monocytes 
did not exhibit increased adhesion when added to CD137-Fc-coated wells.  At the 
lowest concentration of CD137-Fc tested, which was 1 µg/ml, this induction of 
adhesion could still be observed.  On the other hand, there appears to be no difference 
between CD137-expressing and non-expressing cells in their abilities to induce 
monocyte adhesion.  One possible explanation for this might be that the amount of 
CD137 expressed by MCF7/hCD137 variants was lower than the amount of 
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Figure 13.  CD137-Fc, coated at (A) 10 µg/ml, (B) 5 µg/ml and (C) 1 µg/ml, 
promotes adhesion of total PBMCs.  Means ± SD of triplicates are depicted.  * 





3.4  CD137 EXPRESSION ON CANCER CELLS AND PROTECTION  
AGAINST DRUG-MEDIATED CYTOTOXICITY 
 
To determine if cells expressing CD137 are more resistant to the cytotoxic effects of 
chemotherapeutic drugs, MCF7 variants were incubated with different concentrations 
of campthothecin (CPT), a DNA-topoiosomersase 1 inhibitor.  Briefly, after the cells 
were exposed to CPT for 48 h, the extent of cell death was determined by assaying 
the amount of LDH released.  LDH is a stable enzyme found in the cytoplasm of all 
cells, which is released upon cell death and permanent damage to the plasma 
membrane.  Therefore, the level of LDH activity in the supernatant corresponds to 
extent of cell death.  In this experiment, LDH activity was assayed by a colourimetric 
method, in which the colourless tetrazolium salt INT was converted into the red 
formazan dye by the enzyme.   A dose-response curve for each variant  (an example 
of which is shown in Figure 14), was generated by plotting the percentage of cell 
death against log [CPT], and the LC50, defined as the drug concentration required to 
kill 50% of the cells, was determined for each variant.  The lower the LC50, the more 
susceptible the cells were to CPT. 
 
In this set of experiments, four CD137-expressing MCF7 variants, namely 
MCF7/hCD137-3, -33, -15 and -52 were used, with two empty vector-transfected 
variants, MCF7/pcDNA3 and MCF7/pcDNA3A being included as negative controls.  






First, the four CD137-expressing variants were compared with MCF7/pcDNA3 to 
determine if they were more resistant to the cytotoxic effects of CPT.  
MCF7/hCD137-3 cells had a lower LC50 value than MCF7/pcDNA3 cells (0.89 ± 
0.03 vs 1.39 ± 0.08 µM), therefore it was less resistant than MCF7/pcDNA3 cells to 
CPT-induced cytotoxicity.  On the other hand, the opposite was true for 
MCF7/hCD137-33 and -52 cells.  Both had higher LC50 values (2.22 ± 0.18 and 2.58 
± 0.42 µM, respectively) and thus were more resistant to CPT.  The LC50 value of 
the remaining clone MCF7/hCD137-52 did not differ significantly from that of 





































Figure 14.  Cytotoxic effect of CPT on MCF7 variants.  Means ± SD of triplicates 
are depicted.  Similar results were obtained in three independent experiments.  
To verify the above results, the four CD137-expressing variants were compared with 
another control variant, MCF7/pcDNA3A as well.  Surprisingly, the LC50 value of 
MCF7/pcDNA3A cells was 2.78 ± 0.12 µM, which was ~ 2 times that of 
MCF7/pcDNA3.  Although some slight variation in the CPT resistance between the 
two control clones was expected, a two-fold difference was certainly not.  In 





less resistant to CPT, whereas MCF7/hCD137-33 and -15 cells did not differ 
significantly in CPT resistance (p > 0.05 in both cases).         
 
Table 5.  Cytotoxic effect of CPT on MCF7 variants.  Mean LC50 values ± SE of 
three independent experiments are shown.     
Cell line LC50 (uM) 
P value (vs 
MCF7/pcDNA3) 
P value (vs 
MCF7/pcDNA3A) 
MCF7/pcDNA3 1.39 ± 0.08  -  <0.001 
MCF7/pcDNA3A 2.78 ± 0.12 <0.001  -  
MCF7/hCD137-3 0.89 ± 0.03 0.005 <0.001 
MCF7/hCD137-33 2.22 ± 0.18 0.014 0.059 
MCF7/hCD137-15 2.58 ± 0.42 0.048 0.658 
MCF7/hCD137-52 1.25 ± 0.24 0.622 0.005 
 
 
In summary, MCF7/pcDNA3 cells were ~2 times less resistant to CPT than 
MCF7/pcDNA3A cells.   Because of this, different trends were observed when the 
CD137-expressing variants were compared with each control-transfected variant.  
The exception to this was the variant MCF7/hCD137-3, which was less resistant to 





3.5  FUNCTIONAL CHARACTERISATION OF MCF7/HCD137 VARIANTS 
 
As described in sections 3.2-3.4 above, the expression of CD137 by cancer cells does 
not appear to (a) protect the cells from LAK cells-mediated cytotoxicity, (b) promote 
monocyte adhesion and (c) increase resistance to chemotherapeutic drugs. This is in 
contrast to some of the preliminary data obtained using Chinese Hamster Ovary 
(CHO) cells that were similarly transfected with CD137 (refer to Appendix III).  
Gene sequencing results have shown that the plasmid used for generating CD137-
expressing MCF7 variants, CIS, contains no mutation (refer to Appendix III).  Hence, 
this discrepancy in results cannot be attributed to MCF7/hCD137 variants expressing 
a mutated form of CD137.  Nevertheless, it was necessary to confirm that the CD137 
expressed by MCF7/hCD137 variants was indeed functional.       
 
CD137 has been reported to inhibit the proliferation of activated T cells (ref 17).  In 
the case of MM5 and THP-1 cells, increased IL-8 secretion was observed when the 
cells were cultured in the presence of recombinant CD137 protein (Sollner et al. 
2007).  In order to test the functionality of CD137 expressed by MCF7/hCD137 
variants, the ability of these variants to induce the above mentioned effects were 










3.5.1  Effect of CD137 on IL-8 secretion by MM5 and THP-1 cells 
 
 
To determine if CD137-expressing MCF7 cells are able to induce IL-8 secretion in 
MM5 cells, fixed MCF7/hCD137-3 and -33 cells were cultured with MM5 cells for 
24 h.  These two variants were used as they expressed higher levels of CD137 than 
the others (Figure 5C, D).  Two control-transfected variants, MCF7/pcDNA3 and 
MCF7/pcDNA3A were included as negative controls.  Wells coated with CD137-Fc 
or Fc served as positive and negative controls, respectively.  24 h culture supernatants 
were analysed for IL-8 content by sandwich ELISA.    
 
IL-8 production by MM5 cells was greatly increased in the presence of CD137-Fc.  
As compared to Fc-coated wells, a 117-fold increase in IL-8 secretion was observed 
in CD137-Fc-coated wells (<31.3 pg/ml vs 1761.2 ± 149.2 pg/ml).  On the other 
hand, there was no significant difference in IL-8 production induced by the four 
MCF7 variants.  In the presence of MCF7/pcDNA3, MCF7/pcDNA3A, 
MCF7/hCD137-3 and -33 cells, the amounts of IL-8 secreted by MM5 cells were 
57.3 ± 20.9, 47.0 ± 7.7, 58.8 ± 13.1 and 38.0 ± 4.9 pg/ml respectively (Figure 15).  
Thus, while CD137-Fc protein was able to induce IL-8 production in MM5 cells, 

















      
Figure 15.  CD137-Fc, but not CD137-expressing cells induced IL-8 secretion in 
MM5 cells.  Means ± SE are depicted.  Similar results were obtained in two 
independent experiments.  * denotes p < 0.01 as compared to Fc. 
 
 
To confirm these findings, the same experiment was repeated using THP-1 cells 
instead of MM5 cells.  A similar trend was observed in THP-1 as well, albeit the IL-8 
production in CD137-Fc coated wells was lower at 66.3 ± 3.3 pg/ml.  For the 
remaining conditions, the level of IL-8 released was below the detection range of the 
ELISA system used (Table 4).         
 
Table 6.   CD137-Fc, but not CD137-expressing cells induced IL-8 secretion in 
THP-1 cells.  Means ± SE are depicted.  Similar results were obtained in two 
independent experiments.   













Although the expression of CD137 on MCF7/hCD137 variants has been confirmed 
by flow cytometry (Figure 5), it appears that these cells were unable to elicit the same 
effect in MM5 and THP-1 cells as recombinant CD137-Fc.  The most plausible 
explanation for this is that the amount of CD137 expressed on the cells’ surfaces was 
lower than the amount of CD137-Fc that was coated onto wells.  To test this, it was 
first necessary to determine the minimum concentration of CD137-Fc required for the 
induction of IL-8 production in MM5 and THP-1 cells.  This was done by culturing 
MM5 and THP-1 cells in wells coated with various amounts of CD137-Fc and Fc, 
followed by an IL-8 sandwich ELISA using the culture supernatants.  
 
When cultured in wells coated with 10 µg/ml of CD137-Fc, MM5 cells secreted 
significantly more IL-8 as compared to when cultured in wells coated with the same 
amount of Fc protein.  This trend was observed up to the point where the amount of 
CD137-Fc coated was titrated down to a concentration of 0.625 µg/ml (Figure 16), 
beyond which IL-8 levels were below the detection limit of the system.  For cells 
cultured in wells that were coated with corresponding amounts of Fc, the amounts of 

























          
Figure 16.  CD137-Fc induced IL-8 secretion in MM5 cells in a dose-dependent 
manner.  Means ± SE are depicted.  Similar results were obtained in two independent 
experiments.  * denotes p < 0.01 as compared to Fc. 
 
 
Using THP-1 cells for the experiment above, the lowest concentration of CD137-Fc 
required to significantly induce IL-8 production as compared to Fc was found to be 
0.625 µg/ml (Figure 17).  This was identical to the concentration determined for 
MM5 cells (Figure 16).  However, instead of a dose-dependent response, IL-8 
production peaked at 90.4 ± 0.0 pg/ml in wells coated with 2.5 µg/ml of CD137-Fc 
(Figure 17).  For cells cultured in wells that were coated with corresponding amounts 
of Fc, the amounts of IL-8 released were all below the detection limit (data not 
































   
Figure 17.  CD137-Fc induced IL-8 secretion in THP-1 cells.  Means ± SE are 
depicted.  Similar results were obtained in two independent experiments.  * denotes p < 
0.05 as compared to Fc. 
 
In summary, MM5 and THP-1 cells secreted IL-8 when cultured in the presence of 
CD137-Fc.  While this was initially observed using 10 µg/ml of CD137-Fc, it was 
subsequently determined that this effect was still present when only 0.625 µg/ml of 
protein was used.  On the other hand, MCF7/hCD137 variants were unable to induce 
IL-8 secretion in these cells despite expressing CD137.  Therefore, the amount of 
CD137 expressed on MCF7/hCD137 variants was quantified to determine if this lack 
of effect was because these variants expressed less CD137 than the minimum amount 
required to induce IL-8 secretion (refer to Section 3.5.3 below).  
 
 




To determine if MCF7/hCD137 variants are able to inhibit the proliferation of 
activated T cells, PBMCs were cultured in the presence of fixed MCF7 variants or 






lymphocytes among the PBMCs, anti-CD3 antibody was added to the cultures at 
various concentrations.  The proliferation rate of activated T lymphocytes was 
significantly reduced when the cells were cultured in the presence of CD137-Fc 
(Figure 18).  When activated with 1 ng/ml of anti-CD3 mAb, cell proliferation in 
CD137-Fc-coated wells was reduced 5.8-fold as compared to that in Fc-coated wells.  
When 10 ng/ml of anti-CD3 mAb was used, a 3-fold reduction was observed.  On the 
other hand, there was no significant difference in proliferation rates when activated T 
lymphocytes were incubated with the different MCF7 variants.  In the absence of 
anti-CD3, proliferation rates of the cells were negligible.   























Figure 18.  CD137-Fc, but not CD137-expressing cells inhibited the proliferation 
of activated T lymphocytes. Means ± SD of triplicates are depicted.  Similar results 










In summary, although CD137-Fc inhibited the proliferation of activated T 
lymphocytes, CD137-expressing MCF7 cells were unable to induce the same effect.  
This could mean that the CD137 expressed by the cells were non-functional, or that 
the amount of CD137 expressed the MCF7 variants was lower than the amount of 
CD137-Fc that was coated onto wells.   
 
3.5.3  Quantification of CD137 present on MCF7 variants by live cell ELISA 
 
A live cell ELISA was performed using the MCF7 variants to quantify the amount of 
CD137 present on the cells.  A sandwich ELISA was used for MCF7 variants that had 
been resuspended, while a direct ELISA was performed on monolayers of the cells.    
 
Figure 19 below shows the results of the sandwich ELISA.  For the CD137-
expressing variants, the amount of CD137 present decreased with decreasing cell 
numbers. However, for the two empty vector-transfected clones, the amount of 
CD137 present remained approximately constant with decreasing cell numbers.  This 
shows that the capture antibody used for this ELISA was specific in its retention of 
cells that express CD137.  For MCF7/hCD137-3 cells, the amount of CD137 present 
on 5 x 104 cells that had been resuspended was equivalent to that in a well of a 96 
well plate coated with 61.8 ± 2.2 ng/ml of CD137-Fc solution.  The corresponding 
amounts of CD137 present on MCF7/hCD137-33, -15 and -52 cells were 39.5 ± 5.7, 
23.9 ± 2.5 and 19.0 ± 2.4 ng/ml respectively.  MCF7/pcDNA3 and MCF7/pcDNA3A 





The amount of CD137 present on monolayers of MCF7 variant cells were measured 
by direct ELISA.  For MCF7/hCD137-3 cells, the amount of CD137 present on 1 x 
104 cells was equivalent to that in a well of a 96 well plate coated with 14.4 ± 0.1 
ng/ml of CD137-Fc solution (Figure 20).  The corresponding amounts of CD137 
present on MCF7/hCD137-33, -15 and -52 cells were 12.0 ± 1.1, 8.3 ± 0.8 and 7.7 ± 
0.2 ng/ml respectively.  MCF7/pcDNA3 and MCF7/pcDNA3A cells only yielded 
background levels.   
 
From the data above, it appears that the amount of CD137 expressed on 
MCF7/hCD137 variants is much lower than that on CD137-Fc coated surfaces.  This 
might account for why MCF7/hCD137 variants were unable to induce the same 
effects as CD137-Fc in the functional assays above (refer to Sections 3.5.1 and 3.5.2), 







        
























Figure 19.  Quantification of CD137 expressed by MCF7 variants. Means ± SD of 
triplicates are depicted.  Similar results were obtained in three independent experiments.   
 
 
        
















Figure 20.  Quantification of CD137 expressed by MCF7 variants (in monolayer 
format). Means ± SD of triplicates are depicted.  Similar results were obtained in three 













Certain members of the TNFR superfamily, namely TNFR1, 2 (Chan et al. 2000) and 
Fas (Papoff et al. 1999) can form trimers in the absence of ligand binding.  This is 
known as pre-ligand assembly and was subsequently found to be mediated by a 
domain in the extracellular region of the receptors, termed the pre-ligand assembly 
domain (PLAD).  A peptide bearing the same sequence as the PLAD of TNFR1 was 
found to inhibit signal transduction by the receptor (Deng et al. 2005).  Hence, the 
PLAD in members of the TNFR superfamily can potentially be targeted in the 
development of antagonists against the receptors. 
 
While the pre-ligand assembly model has been established in the receptors mentioned 
above, it is unknown whether this is also applicable for CD137.  Despite the fact that 
certain groups have observed the inhibitory effect of soluble CD137 (sCD137) on its 
membrane-bound counterpart (Hurtado et al. 1995), the underlying mechanisms are 
unclear.  For instance, sCD137, which comprises only the extracellular domain of 
CD137, might associate with membrane-bound CD137 to form non-signaling trimers, 
since sCD137 lacks the cytoplasmic domain needed for signal transduction.  This 
phenomenon has been reported in TNFR1 (Deng et al. 2005).  Another possible 
mechanism is the sequestration of CD137L by sCD137, which prevents signaling 






If pre-ligand assembly is indeed the mechanism which underlies the inhibitory effect 
of sCD137, this implies that sCD137 must be able to associate with membrane-bound 
CD137, since the PLAD has to be located within the extracellular domain .To 
determine whether pre-ligand assembly occurs in CD137, the ability of sCD137 to 
associate with membrane-bound CD137 was first investigated.  A series of 
transfections using full length CD137 (flCD137) and sCD137 were performed.    
MCF7 cells were used in these experiments as they are easy to transfect.  This was 
followed by flow cytometry to analyse the levels of CD137 expression on the cells’ 
surfaces, and by ELISA to detect the presence of sCD137 in the supernatants of the 
transfected cells.    
 
When flCD137 alone is transfected, CD137 should be detectable on the cell surface 
and at low, background levels in the supernatant since the receptor is not normally 
secreted.  The converse applies in the case of sCD137, since the resultant protein 
lacks the transmembrane domain and thus cannot be retained on the cells.  When both 
full length and soluble CD137 are co-transfected an increase in cell surface CD137 
expression and a corresponding decrease in CD137 in the supernatant should be 
observed if sCD137 is indeed able to associate with its membrane-bound form.     
 
For the co-transfections, a smaller amount of flCD137 was used as compared to 
sCD137.  This is because, should the cells express too much CD137, any increase in 
surface CD137 due to the incorporation of sCD137 might not be evident.  In these 





As shown in Figure 21A, CD137 staining was negligible (0.1% CD137-positive cells) 
when the empty vector was transfected, since MCF7 cells do not express CD137.  
Similarly, no CD137 was detected on CD137-without transmembrane (CD137-
wotm)-transfected cells, ie cells transfected with sCD137 (0.0% CD137-positive 
cells, Figure 21C).  This is consistent with the fact that without the transmembrane 
domain, sCD137 could not be retained on the cell surface.  Cells that were transfected 
with both CMV-ILA-SEN (CIS) (ie flCD137) and CD137-wotm had more cell 
surface CD137 than cells that were transfected with only CIS.  In this case, an 
increase was observed both in terms of the percentage of CD137-positve cells (12.1% 
vs 8.2%, Figures 21B and D) as well as the mean fluorescence intensity (MFI) of the 
cells (68.0 vs 54.7, Figures 21B and D.  These figures are displayed in a graphical 
form in Figure 22, together with the amount of sCD137 present in the supernatants of 
the cells.   
 
Figure 22 shows that both the control-transfected and CIS-transfected cells gave 
similar background levels of sCD137 at 4.5 ± 0.4 ng/ml and 5.5 ± 0.1 ng/ml, 
respectively.  When CD137-wotm was transfected, 17.6 ± 2.5 ng/ml of sCD137 were 
secreted by the cells, which was more than a 3-fold increase as compared to CIS-
transfected cells.  When both CIS and CD137-wotm were transfected, the amount of 
sCD137 increased further to 32.7 ± 0.3 ng/ml, which was significantly higher 







     A.  pcDNA3 B.  CIS + pcDNA3  
      
    C.  CD137-wotm + pcDNA3                                D.   CIS + CD137-wotm                          
     
Figure 21.  Cell surface expression of CD137 on MCF7 cells transfected according to 
Table 2.  Numbers denote % of CD137-positive cells, followed by MFI. Red histograms: 
isotype control; green histograms: anti-CD137.  Similar results were obtained in three 
independent experiments.   
 
 













Figure 22.   Expression of cell surface and sCD137 in MCF7 cells transfected as per 
Table 2.  For [sCD137], means ± standard deviations of duplicate measurements are 














It is important to note that in CIS + CD137-wotm transfected cells, while there was a 
small increase in cell surface CD137, this could not be attributed to the association of 
sCD137 with membrane-bound CD137.  The reason for this is that there was no 
reduction in the amount of sCD137 present in the supernatants of these cells.  In fact, 
more sCD137 was present as compared to supernatants of CD137-wotm transfected 
cells. This suggests that there was likely an overall increase in protein expression in 
CIS + CD137-wotm-transfected cells.   
 
In another approach, the CD137-wotm plasmid was replaced with CD137-PLAD, 
which is similar to CD137-wotm, except that the resultant protein is fused to a Flag 
and a His tag at the N terminus.  Transfections were performed according to Table 2, 
and the cells were analysed by flow cytometry for the presence of CD137 and Flag.  
The rationale behind this approach is that by staining the cells with both anti-Flag and 
anti-CD137, an increase in the double-positive population would indicate that 
sCD137 was binding to cell surface CD137.  This is likely to be a more sensitive 
method, because low levels of sCD137 association might not be evident if only 
changes in CD137 expression are measured. 
 
The percentage of CD137-positive cells (shown in quadrant R2) was higher in CIS + 
CD137-PLAD- than in CIS-transfected cells (39.6% in the former and 26.0% in the 
latter) (Figures 23B and D. However, the percentage of double-positive cells (i.e. 
cells in quadrant R3) in Figure 23D was 3.0%, as compared to 2.9% in Figure 23B, 





evident increase in Flag levels.  One possible explanation for this is that the protocol 
for Flag detection was not fully optimized, resulting in the absence of Flag staining 
even though sCD137 had associated with membrane-bound CD137, as evidenced by 
presence of more CD137-positive cells.  On the other hand, it must be noted that no 
corresponding ELISA was performed for this set of experiments.  Therefore, the 
increased CD137 expression might also have been due to an overall increase in 
protein expression, as observed in Figure 22.      
 
In summary, although more CD137 was present on the cells’ surface when sCD137 
was co-transfected with flCD137, there was no corresponding reduction in the level 
of sCD137 present in the supernatant.  Therefore, the increase in surface CD137 
could not be attributed to an association of sCD137 with its membrane-bound 
counterpart.  Rather, this phenomenon is more likely to be caused by a general 
increase in protein expression during the co-transfection, of which the mechanisms 






      A.  pcDNA3                                                         B.  CIS + pcDNA3 
 
      C.  CD137-PLAD + pcDNA3                              D.  CIS + CD137-PLAD 
 
Figure 23.  Cell surface expression of CD137 and Flag on MCF7 cells transfected as per 
Table 2.  Cells were stained with anti-CD137 (PE) and anti-Flag (FITC).  Numbers denote the 
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CHAPTER 4  DISCUSSION 
 
 
4.1 OUTLINE OF DISCUSSION 
 
CD137 is a cell surface receptor with a well-established role in T cell co-stimulation 
(Schwarz et al. 1996).  While CD137 has been proposed to confer a survival 
advantage upon cancer cells (Schwarz 2005), little is actually known about its 
potential role as a cancer neoantigen.  However, preliminary data obtained with CHO 
cells demonstrated that cells which overexpress CD137 were more resistant to LAK 
cell- and drug-induced cytotoxicity.  These results suggests that there may be a 
potential link between CD137 expression and cancer progression, and that antagonists 
of CD137 (such as soluble CD137) may be effective in anti-cancer treatment.  To 
verify these preliminary findings, further experiments were performed using stable 
CD137-expressing MCF7 cell lines.  On top of this, the mechanism with which 
soluble CD137 antagonizes the activities of its membrane-bound counterpart was 
investigated. 
 
In this section, the relationship between CD137 expression and the conferment of 
survival advantages upon cancer cells will be discussed based on the results from this 
study.  This will be followed by a discussion on whether pre-ligand assembly is the 
mechanism behind how soluble CD137 is able to antagonize membrane-bound 





4.2 CD137 AS A NEOANTIGEN ON CANCER CELLS 
 
Due to the bidirectional nature of CD137:CD137L signaling, there are two general 
aspects in which the role of CD137 as a cancer neo-antigen can be investigated.  
When CD137 on cancer cells engage CD137L which is expressed on APCs and 
activated T cells, both signaling into the CD137L-expressing cells, as well as 
signaling via CD137 into the cancer cells may potentially be responsible for 
conferring a survival advantage upon cancer cells.  As a result, increased T cell 
apoptosis (Schwarz et al. 1996) and/or enhanced monocyte migration (Drenkard et al. 
2007) to the tumour site might be observed in the former scenario, while the latter 
might lead to upregulation of anti-apoptotic proteins in cancer cells (Lee et al. 2002).     
 
4.2.1 The role of CD137-Fc vs CD137 alone and Fc alone 
 
To investigate how immune cells respond to CD137, cells have been cultured in the 
presence of recombinant CD137-Fc, as described previously (Schwarz et al. 1996) 
and in Sections 3.3 and 3.5 of this thesis.  CD137-Fc is a recombinant fusion protein 
comprising the extracellular domain of CD137 and the Fc portion of the human IgG1 
molecule.  The Fc-tag is commonly used in the production of recombinant proteins 
due to its stabilizing effect on the desired product, as well as the ease of purification 
in downstream processes.  Etanercept (Enbrel®) is an example of a therapeutic 
protein which is tagged with Fc (Gatto 2006).  Since the Fc-tag in CD137-Fc can 





of Fc protein alone as a negative control for non-specific effects induced by Fc 
receptor signaling.  Lastly, untagged recombinant CD137 was not used in this 
investigation because the protein is likely to be less stable than its Fc-tagged 
counterpart.  
 
In the present investigation, MCF7 cells were transfected to overexpress CD137 
rather than CD137-Fc because this resembles physiological conditions more closely, 
ie cells express CD137 and not CD137-Fc in vivo.  In addition, CD137-Fc is secreted 
by cells, thus the plasmid for CD137-Fc cannot be used to generate stable lines that 
express CD137 on the cell surface.  
 
4.2.2 The use of MCF7 cells as the model system 
 
Based on previously reported findings (refer to Chapter 3), it appears that lymphoma-
derived cell lines would be ideal choices for the establishment of a model system for 
this investigation, thus cell lines such as Raji, Ramos and Jurkat were used for 
transfection. However, we were unable to generate CD137-expressing stable lines 
from them due to the low transfection rates in these cells, hence an easily 
transfectable cell line, MCF7 was used instead.  Previous data have shown that 
CD137 confers survival advantages on all of the cell lines that were tested, including 
Chinese Hamster Ovary (CHO) cells, K562 (human chronic myelogenous 
leukaemia), 3T3 (murine fibroblast) and COS-7 (African green monkey kidney cells) 





protects cancer cells, regardless of the cell type.  Therefore, the use of MCF7 as a 
model system is not inappropriate, despite the fact the CD137 has not yet been 
reported to be expressed in breast cancer tissues.  On a side note, it might be possible 
to use the HEK293T cell line for this investigation, given its ease of transfection.  
Although HEK293T cells have been used for CD137 overexpression studies (Jang et 
al. 1998), it is unclear if they express CD137 endogenously.     
 
In a similar study of murine CD137, a B cell lymphoma cell line A20 was used as the 
model system, and the results indicate there CD137 expression does not confer a 
survival advantage upon cancer cells.  This corresponds to, and further supports the 
validity of the findings reported in the present investigation (personal communication, 
H. Schwarz). 
 
4.2.3 CD137 as a cancer neoantigen: effect on LAK-cell mediated cytotoxicity 
 
One of the hypotheses as to how CD137 might confer survival advantages upon 
cancer cells is by inhibiting the cytotoxic activities of effector immune cells.  Results 
from the in vitro LAK cell-mediated cytotoxicity assays unexpectedly indicated a 
significant difference in susceptibility to LAK cells between two different empty 
vector-transfected MCF7 variants (Figures 7 and 8).  Therefore, depending on which 
empty vector-transfected variant was used for comparison, CD137 expression 





As a result of this discrepancy, it was concluded that the role of CD137 expression in 
protecting cancer cells from the cytotoxic effects of LAK cells remains uncertain. 
Regarding the two empty vector-transfected variants, it was indeed surprising to find 
that the difference in susceptibility to LAK cells between them was significant 
enough to result in two different conclusions being drawn.  This difference is likely 
due to random variation during the process of selecting the variants, and highlights 
the importance of using more than one variant in the assays.  The preliminary results 
with CHO cells that suggested a protective effect of CD137 expression were obtained 
using only one CD137-expressing and one empty vector-transfected CHO variant.  
Consequently, the possibility of having observed a false-positive result cannot be 
ruled out. 
 
Another possible explanation for the discrepancy between the CHO and MCF7 
systems was the difference in CD137 expression levels.  CHO/CD137 cells express 
more CD137 than MCF7/hCD137 variants, which in turn have similar expression 
levels as Hodgkin’s lymphoma-derived cell lines that express CD137 endogenously 
(data not shown).  This indicates that higher levels of CD137 expression might be 
necessary to confer resistance against LAK- and drug-mediated cytotoxicity.  One 
might argue that this protective effect of CD137 is an experimental artifact, since it is 
only observed when CD137 expression levels are higher than that on cell lines with 
endogenous CD137 expression.  However, it must be noted that the 
immunohistochemical methods used to detect CD137 are non-quantitative and thus, 





levels of CD137 expression observed in CHO/CD137 cells might still be 
physiologically relevant in the in vivo context. 
In order to overcome the problem stemming from the difference in CPT resistance 
among empty vector-transfected clones, future work can focus on silencing CD137 
expression on MCF7/hCD137 variants to determine if this leads to reduced CPT 
resistance as compared to non-silenced variants.  To this end, some preliminary work 
using short hairpin ribonucleic acid (shRNA) has been done in the present study, but 
the outcome of gene silencing was unsatisfactory (data not shown).  More work can 
be done either to optimize this procedure, or to explore alternatives such as antisense 
oligonucleotides.        
 
To confirm the functionality of the CD137 expressed on MCF7/hCD137 variants, the 
ability of these cells to induce IL-8 secretion in MM5 and THP-1 cells, and to inhibit 
proliferation in activated T cells was determined.  However, MCF7/hCD137 were not 
able to induce the above effects whereas CD137-Fc was (Figures 15 and 18, Table 4).  
Using live cell ELISA, the amount of CD137 expressed on MCF7/hCD137 variants 
was found to be much lower than that on CD137-Fc coated surfaces (Figure 19).  
Furthermore, the variant which expressed the most CD137 (i.e. MCF7/hCD137-3) 
had approximately 10 times less CD137 than the minimum amount required to induce 
IL-8 secretion in MM5 and THP-1 cells (Figures 16, 17 and 19).  While this implies 
that the inability of MCF7/hCD137 variants to induce IL-8 secretion might be due to 
insufficient amounts of CD137 being present, the possibility that the CD137 





findings above, it appears that these functional assays are not sensitive enough for 
determining the functionality of the CD137 expressed on MCF7/hCD137 variants.  
An alternative approach would be to engage CD137 on the cells using recombinant 
CD137L proteins or agonistic anti-CD137 Abs, and to determine the presence of 
signal transduction in the cells.  This can be done by testing for NF-κB activation as 
the effects of CD137 signaling are mediated by the NF-κB pathway (Jang et al. 
1998).  This approach was not adopted in the present study because recombinant 
CD137L protein is supplied in a monomeric form, which is reported to be non-
functional (Rabu et al. 2005).  Also, agonistic anti-CD137 antibodies are not 
commercially available.  However, should these technical limitations be overcome in 
the future, detecting the presence of signal transduction would be a viable alternative 
for the functional characterization of CD137 expressed on cells.             
 
CD137 was proposed to function as a cancer neoantigen based on its ability to induce 
T cell apoptosis (Schwarz et al. 1996), and its ectopic expression on certain cancer 
cells.  However, with respect to the LAK cells used as cytotoxic effector cells in this 
study, most of the cytotoxic activity of these cells is mediated by the NK cell 
population, whereas T cells comprises a small part of the total cell population 
(Schmidt-Wolf et al. 1997).  In order to better observe the effects of CD137-
expressing cancer cells on T cells, it might be worthwhile to perform this cytotoxic 






Preliminary studies showed that CD137-expressing cells were more resistant to LAK 
cell-mediated killing.  Aside from this possibly being a false-positive result (as 
mentioned above), the finding suggests that the original hypothesis of CD137 
inducing apoptosis in T cells is an unlikely explanation for it.  An alternative 
hypothesis of CD137 expression on cancer cells resulting in down-regulation of 
NKG2DLs was thus formed. Subsequently, CD137 and NKG2DL expression were 
found not to be correlated (Figure 9).  One conclusion that can be drawn from these 
finding is that the downregulation of NKG2DL is not the mechanism by which 
CD137 on cancer cells inhibits the cytotoxic activities of LAK cells.  On the other 
hand, it is also possible that CD137 signaling in the MCF7/hCD137 variants was 
absent.  Being a transmembrane receptor, CD137 has to be cross-linked in order to 
initiate signaling into the cells.  It was assumed that for the MCF7/hCD137 variants, 
the overexpression of CD137 by the cells would result in self-oligomerisation of the 
receptor and signal transduction, as previously reported in other overexpression 
studies (Jang et al. 1998). Thus, external agents such as recombinant CD137L protein 
or agonistic anti-CD137 mAbs were not added to the cells to engage CD137.  In 
future studies, it might be necessary to confirm the presence of CD137 signaling in 
MCF7/hCD137 variants.   
 
4.2.4 CD137 as a cancer neoantigen: effect on monocyte adhesion 
 
Total PBMCs were reported to adhere more strongly to CD137-Fc-coated surfaces, 





monocytes were used, more cells were found to have adhered to CD137-Fc-coated 
surfaces as compared to Fc-coated surfaces (Langstein et al. 1998).  In the presence 
of CD137-Fc, adherent monocytes appeared more elongated and spread out, as 
opposed to those in the presence of Fc, which remained round (Langstein & Schwarz 
1999). 
 
In the present study, an assay system was designed to quantify the degree of 
monocyte adhesion in response to CD137 expressed on MCF7/hCD137 variants.  To 
ensure that the system was functioning, CD137-Fc- and Fc-coated surfaces were 
included as positive and negative controls, respectively.  CD137-Fc induced a greater 
degree of cell adhesion in both total PBMCs and monocytes (Figures 10 and 11), 
proving the workability of this system.  Contrary to expectations, the difference in the 
degree of adhesion between CD137-Fc- and Fc-coated surfaces was more pronounced 
in total PBMCs than in monocytes.  To remove the possibility that this observation 
was due to another subpopulation in the PBMCs exhibiting increase adhesion in 
response to CD137, the assay was repeated with the total PBMCs that were depleted 
of monocytes.  Indeed, Figure 12 shows that in the absence of monocytes, there was 
no significant difference in the degree of adhesion induced by CD137-Fc and Fc.  The 
possibility that other cell types in the PBMCs may contribute indirectly to increased 
monocyte adhesion was also considered.  Despite being unlikely, since the difference 
between CD137-Fc and Fc- induced monocyte adhesion could be observed after a 






In the transfected MCF7 variants, CD137 expression did not promote PBMC or 
monocyte adhesion (Figures 10 and 11).  This could be attributed to the lower 
amounts of CD137 present on the MCF7/hCD137 variants than that on CD137-Fc-
coated surfaces, by performing a live cell ELISA on monolayers of MCF7 variants.  
The amount of CD137 present on MCF7/hCD137 variants was approximately 1000 
times less than that on CD137-Fc-coated surfaces (Figure 20).  The possibility of 
CD137-induced monocyte adhesion being an artefact resulting from the high 
concentration of recombinant protein used can be ruled out, since CD137 expression 
was shown to facilitate the infiltration of monocytes into spheroids formed from 
transfected COS cells (Drenkard et al. 2007).  MCF7/hCD137 variants might require 
longer incubation periods with PBMCs/monocytes in order to exert the same effect as 
recombinant CD137-Fc.  To explore this possibility, attempts to increase the 
incubation time were made.  However, a general decrease (to nearly background 
levels) in the degree of cell adhesion was observed after overnight incubation, and 
there was no significant difference among all the various treatments (data not shown).  
This general decrease is likely to be attributed to the leakage of fluorescent dye from 
the labeled cells, and the problem remained unresolved with the use of an alternative 
fluorescent probe (specifically, CellTrace™ CFSE instead of Calcein AM, both from 
Molecular Probes).  Taken the above observations into consideration, the current 
assay system might not be adequate for quantifying the degree of monocyte adhesion 
induced by CD137-expressing cells.  Future improvements to the experimental setup 
may include the substitution of fluorescent probes with others which are more stable 








4.2.5 CD137 as a cancer neoantigen: effect on drug-mediated cytotoxicity 
 
Similar to what was observed in the LAK cell-mediated cytotoxicity assay, there was 
a significant difference in CPT resistance between the two empty vector-transfected 
variants.  MCF7/pcDNA3A cells were found to be approximately twice as resistant to 
CPT as MCF7/pcDNA3 cells (Table 3), just as they were also more resistant to LAK 
cell-mediated cytotoxicity (Figures 7 and 8).  These findings point to the 
MCF7/pcDNA3 variant as being less robust than its counterpart, hence leading to 
contradictory results regarding whether CD137-expressing cells are more resistant to 
CPT.  Nevertheless, among the MCF7/hCD137 variants, resistance to CPT is not 
correlated with the level of CD137 expression (refer to Figure 5 and Table 3).  In fact, 
considering the large difference in CPT resistance between the two control variants, 
the variation in CPT resistance among the MCF7/hCD137 variants might simply have 
resulted from random chance.  Once again, these findings highlight the importance of 
using more than one variant for comparison.  Given the current data, there is no 
conclusive evidence to show that the expression of CD137 on cancer cells can protect 
them from drug-mediated cytotoxicity. 
 
There are a few possible explanations for why CD137-expressing cancer cells are not 





cells.  One of them is: CD137-induced upregulation of the anti-apoptotic proteins 
Bcl-XL and Bfl-1 has hitherto been reported only in T cells (Lee et al. 2002).  While 
CD137 signaling does result in NF-κB activation in non-T cells (Jang et al. 1998), it 
is unknown whether this also leads to the upregulation of the two anti-apoptotic 
proteins.  Hence, it is possible that signaling through CD137 does not prevent 
apoptosis in MCF7/hCD137 variants, simply because the downstream signaling 
involved in the breast carcinoma cell line might differ from that in T cells.   Another 
explanation for the current findings has already been given in Section 4.2.1 above, i.e 
the assumption that overexpression of CD137 in MCF7/hCD137 variants initiates 
signaling through the receptor might not be valid.  Lastly, it is also possible that the 
level of CD137 expression on the MCF7/hCD137 variants was too low to exert a 
protective effect against CPT.       
  
4.3 THE PRE-LIGAND ASSEMBLY MODEL AND ITS RELEVANCE TO 
CD137      
 
The pre-ligand assembly model describes how certain receptors belonging to the 
TNFR superfamily exist as pre-assembled oligomers prior to ligand binding.  This 
phenomenon has been proposed to be biologically significant in a number of ways, 
and is particularly important for ensuring correct signal transduction in receptors 
which bind to the same ligand, such as TNFR-1 and -2 (Chan 2007).  Based on this 
model, a TNFR-1 antagonist which comprises the pre-ligand assembly domain 






To determine if the pre-ligand assembly model also applies to CD137, the present 
study aimed to find out if sCD137 was able to associate with membrane-bound 
CD137.  Results indicated that this was likely not to be the case.  When flCD137 and 
sCD137 were co-transfected into MCF7 cells, while there was an increase in the 
amount of CD137 present on the cells, this was not accompanied by a corresponding 
decrease in the sCD137 levels in the supernatant (Figures 21 and 22).  In other words, 
the increase in CD137 levels could not be attributed to the association of sCD137 
with its membrane-bound counterpart, but rather, it appears to be a result of an overall 
increase in protein expression.   
 
This finding points to a drawback in the experimental setup.  Despite having 
transfected the same quantity of plasmid DNA for all the different conditions (refer to 
Table 2 in Section 2.16.1), it was not possible to ensure that the transfection efficacy 
for all the conditions was the same.  Therefore, it was possible that in the flCD137 
and sCD137 co-transfected cells, the reduction in sCD137 resulting from association 
with membrane-bound CD137 had been masked by increased sCD137 production.  In 
future studies, it might be necessary to include a third plasmid bearing a reporter gene 
such as luciferase.  The level of reporter gene expression can thus serve as an internal 
control and be used to normalize any differences in transfection efficacy between the 






In another set of experiments, a Flag-tagged form of sCD137 was used instead of the 
unmodified form.  The presence of CD137- and Flag-double positive cells would 
indicate that sCD137 is able to associate with membrane-bound CD137.  As Flag is 
not normally present on the cells, even small differences in the amount of Flag 
present would appear more evident.  Hence, this method was thought to be more 
sensitive as compared to measuring differences in the amount of cell surface CD137.  
A larger proportion of cells transfected with both flCD137 and sCD137 was CD137-
positive as compared to cells transfected with flCD137 alone, but the proportion of 
CD137- and Flag-double positive cells remained approximately the same (Figure 23).  
Since a corresponding ELISA for sCD137 was not performed, it remains unclear if 
these results were due to an overall increase in protein expression, or due to a sub-
optimal staining protocol for Flag.  For this part of the study, future work may 
involve optimizing the protocol for the staining and detection of Flag on the 
transfected cells.    
 
From the results of this investigation, there appears to be no evidence pointing to 
sCD137 being able to associate with membrane-bound CD137.  In other words, the 
pre-ligand assembly model might not apply to CD137.  This in turn implies that the 
inhibitory effect of sCD137 on membrane-bound CD137 (Michel & Schwarz 2000) is 






4.4  FUTURE DIRECTIONS 
 
The potential role of CD137 as a cancer neoantigen was investigated in the present 
study by overexpressing the receptor in MCF7 cells.  Other aspects of this 
investigation which can be explored and/or improved on have already been 
mentioned in the sections above.  On top of this, a gene knock-down approach can be 
adopted to complement the findings from this study. This involves the screening of 
cancer cell lines to identify those which express CD137 constitutively, followed by 
the silencing of CD137 and the generation of stable CD137-silenced variants.  Certain 
cell lines which are derived from Hodgkin’s lymphoma and exhibit characteristics of 
Reed Sternberg cells do express CD137 constitutively (Gruss et al. 1996a; Gruss et 
al. 1996b).  Examples include KM-H2 and HDLM-2, both of which are possible 
candidates for such a gene knock-down study.  
 
Instead of using flow cytometry, the question of whether sCD137 is able to associate 
with membrane-bound CD137 can be further examined using western blotting and 
immunoprecipitation.  If CD137 is found to undergo pre-ligand assembly, future 
work would involve mapping and characterizing the PLAD in CD137.  Otherwise, 
more studies can be done to investigate other potential mechanisms by which sCD137 





CHAPTER 5  CONCLUSION 
 
 
CD137 functions as a co-stimulatory receptor on T cells, and this property has been 
utilized for the enhancement T cell activities in anti-cancer immunotherapy.  CD137 
was also found on B cells in CLL but not on corresponding healthy B cells, which 
implied that the receptor might have a novel role as a cancer neoantigen.  In the 
present study, there is no conclusive evidence showing that CD137-expressing cancer 
cells were protected against LAK cell- and drug-mediated cytotoxicity.  Nevertheless, 
given the complex nature of the immune system, these findings do not necessarily 
mean that CD137 does not confer a survival advantage upon cancer cells in vivo.  
More work is thus required to elucidate the relationship between CD137 expression 
and cancer progression.   
 
In addition, results from the present study indicate that sCD137 may not associate 
with membrane-bound CD137.  This in turn implies that the pre-ligand assembly 
model might not apply to CD137, and that sCD137 possibly inhibits CD137-mediated 
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 APPENDIX I  MATERIALS FOR CELL CULTURE 
 
1. Dulbecco's Modified Eagle Medium (DMEM) 
 
To prepare 1 L of medium: 
 
Item Quantity Source 
DMEM powder 17.6 g Sigma-Aldrich (St Louis, MO) 
L-glutamine (100x) 10 ml Gibco, Invitrogen (Carlsbad, CA) 
Sodium  bicarbonate 3.7 g US Biological (Swampscott, MA) 
MilliQ water 1 L - 
 




To prepare 500 ml of medium: 
      
Item Quantity Source 
DMEM medium 450 ml - 




To prepare 1 L of medium: 
      
Item Quantity Source 
RPMI powder 16.35 g Sigma-Aldrich (St Louis, MO) 
L-glutamine (100x) 10 ml Gibco, Invitrogen (Carlsbad, CA) 
Sodium  bicarbonate 2 g US Biological (Swampscott, MA) 







The medium was then sterile-filtered through a 0.22um filter membrane. 
 
4.  RPMI-10 
 
 
To prepare 500ml of medium: 
      
Item Quantity Source 
RPMI medium 450 ml  -  




5.  Phosphate Buffered Saline (PBS) 
 
 
To prepare 1 L of solution: 
 
Item Quantity Source 
NaCl 8 g Sigma-Aldrich (St Louis, MO) 
KCl 0.2 g Sigma-Aldrich (St Louis, MO) 
Na2HPO4 1.44 g Sigma-Aldrich (St Louis, MO) 
KH2PO4 0.24 g Sigma-Aldrich (St Louis, MO) 
MilliQ water 1 L  -  
 
 
      The solution was sterilized by autoclaving after its pH was adjusted to 7.4. 
 
 
6. 10 mM EDTA in PBS 
 
 
To prepare 50 ml of solution: 
      
Item Quantity Source 
0.5M EDTA solution 1 ml NUMI store 
MilliQ water 49 ml   - 
 
 







7. RBC lysis buffer 
 
To prepare 500 ml of solution: 
   
Item Quantity Source 
NH4Cl 4.145 g Sigma-Aldrich (St Louis, MO) 
NaHCO3 0.42 g Sigma-Aldrich (St Louis, MO) 
0.5M EDTA solution 11.5 ul NUMI store 
MilliQ water 500 ml  -  
 
 
The solution was then sterile-filtered through a 0.22um filter membrane. 
 
 
8. Lysis buffer 
 
 
To prepare 50 ml of solution: 
 
   
Item Quantity Source 
Triton X-100 50 ul Bio-Rad (Hercules, CA) 
Sodium borate  Sigma-Aldrich (St Louis, MO) 
MilliQ water 50 ml  -  
 
 





APPENDIX II  MATERIALS FOR FLOW CYTOMETRY AND 
ELISA 
 
1. FACS buffer 
 
To prepare 500 ml of buffer: 
   
Item Quantity Source 
FBS 2.5 ml Biowest (Nuaville, France) 
NaN3 0.1 g Sigma-Aldrich (St Louis, MO) 
PBS 500 ml  -  
   
 
2. Blocking buffer for live cell ELISA 
 
 
To prepare 500 ml of buffer: 
 
Item Quantity Source 
BSA 5 g Bioclot (Australia) 
PBS 500 ml  -  
 
 
3. 0.05M Phosphate Citrate buffer (for TMB substrate solution) 
 
 
To prepare 100 ml of buffer: 
 
Item Quantity Source 
0.2 M Na2HPO4 solution 25.7 ml Sigma-Aldrich (St Louis, MO) 
0.1 M citric acid 24.3 ml Sigma-Aldrich (St Louis, MO) 
 
 
The pH of the solution was adjusted to 5.0 and the volume was topped up to 100 












4. TMB substrate solution 
 
To prepare 10 ml of solution: 
   
Item Quantity Source 
TMB tablet 1 tablet Sigma-Aldrich (St Louis, MO) 
0.05 M phosphate 
citrate buffer 10 ml  -  
30% H2O2 2 ul Kanto Chemicals (Japan) 




To prepare 1 L of solution: 
   
Item Quantity Source 
Tween-20 500 µl Bio-Rad, Hercules, CA 
PBS 1 L  -  
 
 
6.  Binding buffer for α-Flag mAb 
 
To prepare 500 ml of buffer: 
   
Item Quantity Source 
FBS 25ml Biowest (Nuaville, France) 
NaN3 1g Sigma-Aldrich (St Louis, MO) 
PBS 500ml  -  
  
 
7. Blocking buffer for CD137 ELISA 
 
To prepare 100 ml of buffer: 
   
Item Quantity Source 
BSA 3g Bioclot, Australia 





APPENDIX III  PRELIMINARY DATA 
 
 

















Figure 24.  CD137-expressing CHO cells were less susceptible to LAK cells-induced 
cytotoxicity.  Means ± SD of duplicates are depicted.  Similar results were obtained in 


































Figure 25.  CD137-expressing CHO cells were less susceptible to CPT-induced 
cytotoxicity.  Means ± SD of duplicates are depicted.  Similar results were obtained 
in two independent experiments.     
 
 
